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Isolation of Ocular Hypotensive Agents 
From Cannabis sativa 
HOWARD M. DEUTSCH, Ph.D., KEITH GREEN, Ph.D., and LEON H. ZALKOW, Ph.D. 
Atlanta, Ga., and Augusta, Ga. 
Abstract: Recent work in our laboratories has shown that a hydrophilic fraction from 
Cannabis sativa (marihuana) has extremely potent intraocular pressure (IOP)-
lowering activity as measured in albino rabbits when delivered by intravenous injec-
tion. A crude extract reduced 10P by 50-60 per cent (to the episcleral venous pressure) 
at dosage levels of about 500 Jug/animal. Fractionation of this material by solvent 
extraction, high-performance liquid chromatography, and gel filtration chromatog-
raphy has produced samples with high activity at 50 Ag/animal. The active material 
has been shown to be noncannabinoid and of high molecular weight. 
CANNABIS SATIVA (marihuana) has had  an interesting history as a medicinal 
plant and intoxicant for at least the last 
several thousand years. The chemistry of 
this plant has been intensively studied for 
many years, and a recent review identified 
some 420 natural products that have been 
isolated.' The medical use of marihuana in 
the United States ended about 1937. In the 
early 1960s, the rapid expansion of the ille-
gal use of cannabis encouraged new inves-
tigations into the effects of marihuana con-
sumption. It was not until 1964 that it was 
shown that the main psychoactive corn-
pount in cannabis was Y-tetrahydrocan-
nabinol (THC).2 
In terms of the ocular response to canna-
bis, it had been known for many years that 
smoking or oral consumption causes con-
juctival hyperemia.' However, it was not 
until 1971 that Hepler and Frank 4 reported 
a lowering of intraocular pressure (IOP). 
They found that when marihuana cigarettes 
containing 18 mg THC were smoked, the 
IOP of 13 normotensive volunteers changed 
From the School of Chemistry, Georgia Institute of 
Technology, Atlanta, Ga. 30332; and the Departments 
of Ophthalmology and Physiology, MCG Box 3059, 
Medical College of Georgia, Augusta, Ga. 30901. 
by +4 to —45 per cent, averaging about —25 
per cent. These findings were confirmed in 
other studies with both normotensive and 
hypertensive volunteers 3 " and in exten-
sive animal studies, primarily by Green 
and co-workers.' 
In summary, it can be stated that mari-
huana, THC, and several other related 
compounds have good activity in lowering 
IOP and thus have the potential to be useful 
in the treatment of glaucoma. However, as 
of this time, an effective, nonpsychoactive, 
and easy to deliver cannabinoid drug has 
yet to be developed and to be shown to lower 
IOP and save vision. 
In 1978, an unusual report appeared' in-
dicating that a nonpsychoactive prepara-
tion had been made from marihuana that 
was useful in the treatment of glaucoma. 
Since the details of the experimental work 
were not included, it was not possible to 
determine how these "Cannabis Eye Drops" 
were prepared or tested, either in glauco-
matous volunteers or in test animals. For a 
number of reasons we assumed that the 
solvent used to prepare this "nonpsychoac-
tive" material must have been water. How-
ever, we were unable to demonstrate any 
topical activity in rabbits using water ex- 
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tracts. On the other hand, intravenous in-
jections of the crude aqueous extract of 
Cannabis sativa showed very strong TOP-
lowering activity in rabbits, and such an 
extract forms the basis for the work re-
ported herein. 8 
Methods 
Samples of Cannabis sativa (Mexican) 
were obtained from the University of Mis-
sissippi Research Institute of Pharmaceut-
ical Sciences through the auspices of the 
National Institute of Drug Abuse (NIDA). 
The plant material was ground and ex-
tracted with water. The water extract was 
filtered and then freeze dried. Liquid chro-
matographic separations were performed 
on either a Water's Prep 500 system or a 
Laboratory Data Control System using C-
18 reverse-phase columns. Continuous ex-
tractions of solid extract were done in a 
Soxhlet apparatus. Samples were dialyzed 
against distilled water using cellulose tub-
ing with a 12,000 molecular weight cutoff 
(Fisher). Gel filtration chromatography 
was performed with Pharmacia Sephadex 
G-25 resin in a column 20 X 2.5 cm using 
distilled water as eluant and ultraviolet de-
tection at 254 nm. Ion exchange chromatog-
raphy was done on DEAE cellulose (What-
man D-52) using 0.05 M Tris buffer (Sigma) 
adjusted to pH 6.7 with hydrochloric acid; 
the ionic strength varied with sodium chlo-
ride. A column 35 X 2.5 cm was used with 
the above solvents, and detection was at 
254 nm. Carbohydrate analyses were done 
by the phenol-sulfuric acid method,' whereas 
protein was analyzed by the method of 
Lowry.' 
IOP screening was performed in adult al-
bino rabbits (two to six were used for each 
test) weighing 2.5 to 3.5 kg each, of either 
sex. Before the initial application of a topi-
cal drop or intravenous injection, a baseline 
IOP was obtained; two readings of IOP 
were made 30 minutes apart using an Alcon 
Pneumotonograph calibrated for the rabbit 
eye. After delivery of the drug, readings  
were taken hourly up to 7 hours and then 
usually at 24 hours. In some experiments, 
other time periods were employed. Rabbits 
were preconditioned to the laboratory re-
gime prior to the drug testing procedure. 
Error analysis for IOP readings at each 
time period showed that with two rabbits 
(four eyes), the standard error was usually 5 
to 12 per cent change in IOP; with six rab-
bits (12 eyes), the standard error was usu-
ally 2 to 6 per cent change in IOP. 
Results 
The water extract contained approxi-
mately 2.7 Gm dissolved solids per 100 ml, 
and the total solids represented about 22 
per cent by weight of the air-dried plant. 
Topical application of the water extract on 
rabbit eyes resulted in no significant change 
in IOP. Consequently, intravenous injec-
tion was tried. Activity was observed at 1.0 
and 0.1 ml per animal (Fig. 1). As will be 
detailed later, the pattern of change involv- 
TIME-HOURS 
Fig. 1. Effect of intravenous aqueous extract of 
Cannabis sativa on rabbit 10P: (.) 1.0 ml ( — 25 
mg solids); (o)0.1 ml (--•• 2.5 mg solids); (.1)0.01 ml 
( •-• 0.25 mg solids); 
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Fig. 2. IOP testing of fractions from reverse-
phase chromatography. Intravenous injection in 
rabbits at 0.5 mg per animal: (A) fraction 1—most 
polar; (4) fraction 2--less polar; (o) fraction 3—
least polar. 
Fig. 3. IOP testing of material from Soxhlet ex-
traction of freeze-dried extract. Material soluble 
in water, but not soluble in n-butanol, acetone, or 
methanol: (A) 0.50 mg per animal; (0)0.25 mg per 
animal; (o) 0.10 mg per animal; 
ELUTION VOLUME — ml 
0.25 M—N6CI 0.5 M NaCI 


















Fig. 4. IOP testing of dialysis fractions. Intra-
venous injection in rabbits at 0.20 mg per animal: 
(o) retentate; (•) dialyzate. 
ELUTION VOLUME —161 
Fig. 5. Chromatography of aqueous extract of 
Cannabis sativa. Top, Sephadex G-25 gel filtra-
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Fig. 6.10P testing of fractions from gel filtration 
chromatography on Sephadex G-25. Intravenous 
injection in rabbits at 0.20 mg per animal: (o) 
void volume material; (•) later eluting material, 
ing an initial ocular hypertensive phase fol-
lowed by the rapid onset of a very powerful 
hypotensive effect is quite typical. 
Initial attempts to fractionate the extract 
centered on liquid chromatography. High-
performance liquid chromatography (HPLC) 
using a low loaded C-18 reverse-phase col-
umn and water as the eluting solvent indi-
cated that some separation of material was 
possible under analytical conditions using 
UV detection at 254 nm. Therefore, a large-
scale separation was made using the Wa-
ter's Prep 500 equipped with a similar col-
umn. The refractive index detector did not 
reveal any clear separation; a large number 
of fractions were taken and each analyzed 
for TOP-lowering activity. Thus, 10.0 Gm 
freeze-dried extract was stirred with 100 ml 
water for 1 hour and filtered, leaving about 
3 Gm insoluble dark material. The solution 
was injected on the column, and after elu-
tion of the void volume, fractions were 
taken. The first 500 ml contained 4.51 Gm 
(64 per cent) inactive material. The next 500  
ml contained 0.56 Gm (8 per cent) active 
material. The balance of the eluted material 
(solvent 100% water to 100% methanol) was 
1.21 Gm (17 per cent) and was inactive. The 
results of TOP screening of these fractions 
are shown in Fig. 2. 
Although the above procedure did frac-
tionate some active material, other meth-
ods of purification were sought. One sim-
ple procedure was solvent extraction of the 
freeze-dried solid with various organic sol-
vents. When 18.33 Gm freeze-dried extract 
was extracted successively with n-butanol, 
acetone, and methanol, fractions were ob-
tained that contained 0.68 Gm (3.7 per 
cent), 0.51 Gm (2.8 per cent), and 6.07 Gm 
(33.1 per cent), respectively. None of these 
was active. The residue (ca 11 Gm) was 
washed with a large volume of hot water, 
and the clear, dark solution was freeze 
dried. This yielded 7.4 Gm (40 per cent) 
material that was quite active. Figure 3 
summarizes TOP screening of this fraction. 
TIME-HOURS 
Fig. 7. lOP testing of fractions from DEAE cellu-
lose ion exchange chromatography. Intravenous 
injection in rabbits at 0.20 mg per animal: (o) 
fraction 1 (buffer only); (el) fraction 2 (buffer plus 
















OCULAR HYPOTENSIVE AGENTS FROM CANNABIS 
Since the active material seemed to be 
totally insoluble even in polar organic sol-
vents but readily Eoluble in water, the pos-
sibility of the active material being poly-
meric in nature was investigated by dialysis. 
In one experiment, 112.8 mg was dialyzed 
twice for 24 hours each. The retentate and 
dialyzate were freeze-dried to yield 22.4 mg 
(19.9 per cent) and 88.6 mg (78.5 per cent), 
respectively. Screening of these material is 
shown in Fig. 4 which shows the high activ-
ity of the retained material versus the 
dialyzate. 
Similar results were obtained on gel fil-
tration chromatography, as shown in part 
of Fig. 5. When 60.0 mg material was chro-
matographed using water as the eluting 
solvent, the first material eluted off the col-
umn (void volume) gave 10.2 mg, with the 
later eluting material yielding 46.6 mg. IOP 
screening of these fractions (Fig. 6) indi-
cated that the activity was in the void vol-
ume material. 
Another separation was achieved when 
199 mg extract was chromatographed on 
the ion exchange resin DE-52 (DEAE cellu-
lose). In this experiment the eluting sol-
vent, in all cases, was 0.05M Tris buffer at 
pH 6.7. After the first fraction was eluted 
(15.3 mg), the ionic strength was changed to 
include 0.25MNaC1, and this gave a second 
fraction (10.8 mg); a third fraction was ob-
tained at 0.50M NaCl (10.4 mg). This chro-
matography is shown as part of Fig. 5. All 
fractions were dialyzed to remove buffer 
and salt and therefore contain no low-
molecular-weight material. The IOP screen-
ing results for these fractions are summar-
ized in Fig. 7. 
The first fraction eluted off the G-25 
column (void volume fraction) was ana-
lyzed for carbohydrate using D-glucose and 
D-galactose (1:1.5) as a standard. Duplicate 
analyses gave 33.4 and 36.5% carbo-
hydrate. This fraction also gave a strong 
positive color reaction for protein. 
Discussion 
The aqueous extract of Cannabis sativa 
obviously contains compound(s) with ex-
tremely powerful IOP-lowering activity 
when delivered intravenously to rabbits. 
The crude extract shows this activity at 
about 2.7 mg per animal but not at 0.27 mg 
per animal. Characteristically, there is a 
rise in IOP at 1 to 2 hours after injection and 
then a very rapid fall in IOP at 3 to 4 hours. 
With sufficient dose, the IOP falls to about 
60 per cent below baseline, which ap-
proaches the maximum fall possible since 
the absolute IOP is reduced to the normal 
episcleral venous pressure. None of the 
other drugs commonly used in glaucoma 
therapy has such a dramatic effect. 
Liquid chromatography was used to try 
to fractionate these crude extracts. Al-
though separation of active fractions was 
achieved, the expected increase in activity 
was not observed. A simpler method of pur-
ification, namely, extraction of the freeze-
dried solid first with organic solvents and 
then with water, produced material that 
was very active at 100 Al g per animal (and in 
some experiments at even lower dosages). 
The chemical nature of these active com-
pound(s) was revealed from dialysis exper-
iments. The retentate, which represented 
about 20 per cent of the crude fraction, had 
very high activity at 200 /.4g per animal, 
whereas the dialyzate was inactive at the 
same dosage. It would thus appear that the 
active material was a high-molecular-
weight polymer. This was confirmed by gel 
filtration chromatography on Sephadex G-
25; the void volume eluting material was 
active at 200 j./g per animal, whereas the 
later eluting material was inactive. 
Some information as to the ionic nature 
of the active compound(s) was obtained by 
chromatography on DEAE cellulose. The 
least acidic material, which was eluted 
with 0.05M Tris buffer at pH 6.7, had the 
highest IOP-lowering activity. More acidic 
fractions that eluted at higher ionic strength 
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showed weaker but real activity (confirmed 
at higher dosages). 
The active material, eluting at the void 
volume in gel filtration chromatography, 
was quantitatively analyzed for carbohy-
drate using the phenol-sulfuric acid method. 
This showed that the material contained 
about 35 per cent carbohydrate. Protein 
analysis has shown a strong positive test 
by the Lowry method. 
These results are consistent with those of 
Wold et al. 1-13 who have found and par-
tially characterized a glycoprotein from 
aqeuous extracts of South African and Thai 
Cannabis sativa. 
Summary 
The aqueous extract of Cannabis sativa 
(Mexican) has been shown to contain com-
pound(s) with very powerful intraocular 
pressure (IOP)-lowering activity. This 
screening was done by intravenous injec-
ton in albino rabbits. Topical application of 
this extract did not lower IOP. The aqueous 
extract has been fractionated in a number 
of ways. It has been shown that the active 
component(s) are of high molecular weight 
as indicated by dialysis experiments and 
by gel filtration chromatography. Ion ex-
change chromatography has given indica-
tions that there may be more than one ac-
tive component; the least acidic of these 
appears to have the greatest activity. Pre-
liminary analysis of the high-molecular-
weight fraction from gel chromatography 
has shown that it contains a considerable 
amount of carbohydrate and protein. 
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ABSTRACT 
A water soluble material, isolated from 
Cannabis sativa, has been tested in albino and 
pigmented rabbits and rhesus monkeys for both 
ocular and systemic effects. Intravenous adminis-
tration produced a dose-related fall in intra-
ocular pressure in both albino and pigmented 
rabbits with concentrations as low as 0.005 mg/ 
animal being effective, but no response was found 
in monkeys. High concentrations (0.2 to 1 mg/ 
animal) induced a hypertensive phase in intraocular 
pressure prior to the ocular hypotension; higher 
concentrations (2 or 5 mg/animal) also induced 
antidiuresis and general relaxation. Tachyphylaxis 
was found to repeated daily injections. Alpha and 
8-adrenergic antagonists caused some reduction of 
the hypertensive phase but had no effect on the 
hypotensive phase. Superior cervical ganglionect-
omy did not influence the time course of the 
intraocular pressure response. Indomethacin in-
hibited the hypertensive intraocular pressure 
phase but was ineffective against the hypotensive 
phase. Systemic blood pressure was unchanged 
following intravenous administration of 0.2 mg 
material/animal. Aqueous humor protein concentra-
tion was increased at both 1 and 6 hours after 
intravenous administration, becoming greater at 
the later time. Aqueous humor turnover rate was 
substantially reduced reaching a minimum 8.75 
hours after administration. Topical administration 
was ineffective in eyes when the epithelium was 
removed in rabbits with and without pretreatment 
with aspirin. Neither gastric nor suppository 
administration of large quantities (10 mg or 
greater) of material had any influence on intra-
ocular pressure. 
INTRODUCTION 
The chemical constituents of marihuana, Cannabis  
sativa, L, are well-known (1), and most of the 
pharmacological studies on marihuana extracts have 
been directed towards comprehension of the effects 
of cannabinoids. The cannabinoids have been 
identified as evoking the majority of the pharma-
cological effects of marihuana and are associated 
with the well-recognized euphoric or psychoactive 
effects of the parent material (2,3). The ocular 
effects of marihuana and the cannabinoids have  
been documented in both man and animals (4). 
The cannabinoids are exclusively soluble in 
organic solvents, but also present in the plant 
material are water soluble compounds. Some of 
the physiological and pharmacological activities 
of certain of these compounds have been indicated 
previously. These activities include atropinic 
and muscarinic-like action (5), as well as aldose 
reductase inhibition (6). 
An extract of Cannabis, for which the solvent 
was not specified, was described as acutely re-
ducing the intraocular pressure (IOP) of dogs. 
When used in man as topical drops, aprogressive fall 
in IOP occurred over a period of about 6weeks (7). 
This study indicated that other biologically 
active compounds could be extracted from Cannabis  
which caused ocular changes and our studies were 
directed towards comprehension of the effect of 
water soluble compounds on IOP and their mode of 
action. 
MATERIALS AND METHODS 
Drugs and preparation  
Cannabis sativa L, Mexican variety, was supplied 
by the University of Mississippi, Research 
Institute of Pharmaceutical Sciences. Water 
extracts were prepared as described previously (8) 
and various materials, prepared by various chroma-
tographic techniques, were screened for IOP re-
ducing activity using an initial intravenous test 
dose of 0.2 mg/animal. 
Following the initial identification of a 
specifically active material which caused a marked 
fall in IOP, this drug was chosen to investigate 
the pharmacological activity. The material of 
choice (marihuana - derived material or MDM) was 





that remaining after Soxhlet extraction of freeze 
dried crude water extract which was insoluble in 
butyl alcohol, acetone or methanol but which was 
water soluble (8). This material was by far the 
most potent of those extracted, markedly reducing 
IOP when given intravenously, with its extraction 
from the crude material being duplicated with ease. 
The MDM was readily soluble in water and each 
solution was made up fresh in 0.9% saline. 
Irrespective of the amount of MDM administered per 
animal the volume was 1 ml for intravenous injection. 
Animal testing  
Rabbits. Both albino and pigmented rabbits (2.3 
kg) were used. 
a) IOP determinations. Animals were restrained 
in canvas bags tied at the neck and the IOP measured 
using a calibrated Alcon Pneumatonograph. Corneas 
were anesthetized with one drop of tetracaine 
(proparacaine hydrochloride) which was washed off 
after 5 to 10 seconds with at least 1 ml of 0.9% 
saline. Measurements were made (relative to the 
time of drug administration) at -40 min., -30 min, 
0, and at each successive hour up to 7 hours on 
each test day. Frequently a 24 hour hour reading 
was made. The -40 min. reading was discarded and 
the -30 and 0 values were averaged to provide a 
mean time-zero value for each rabbit. Percentage 
changes in IOP were calculat2d relative to the 
time-zero prior to statistical analysis. Control 
series were frequently performed to determine any 
non-drug related changes occurring with time. MDM 
was also boiled for 30 minutes and administered 
intravenously at 1 mg/animal. 
b) Antagonists. Several drugs were used as 
potential antagonists; a-adrenergic blocking 
agents, phenoxybenzamine and phentolamine or S-
adrenergic blocking agents, sotalol and propranol-
ol were used at 0.5 or 5 mg/kg and were all given 
intravenously. Timolol (Timoptic), 0.5%, was 
unilaterally applied topically 1 hour prior to 
intravenous MDM and every hour thereafter up to 
8 hours. Indomethacin (20 mg/kg) was given 
intraperitoneally. Hexamethonium chloride and 
tripelennamine, an antihistamine, were both given 
intravenously at 10 mg/kg and 2 or 4 mg/kg,  
respectively. The adrenergic antagonists, as well 
as indomethacin and tripelennamine were all given 
at 0 time with MDM given 1 hour later. IOP changes 
given are relative to the intravenous administrat-
ion of MDM. Hexamethonium chloride was given 6 
hours after the intravenous MDM. 
Animals were anesthetized with xylazine and 
ketamine for the unilateral surgical removal of a 
superior cervical ganglion. At 10 days post 
surgery, eyes were tested for adrenergic super-
sensitivity with 0.1% norepinephrine administered 
to both eyes. Successful surgery was adjudged by 
mydriasis in the eye of the operated side. 
Animals were used at least 3 days following 
testing for supersensitivity. 
c) Topical administration. MDM was dissolved 
in 0.9% saline at various concentrations from 1 to 
10% and applied unilaterally in a topical 50 pl 
drop in the presence and absence of benzalkonium 
chloride or cetylpyridinium chloride. In some 
experiments the corneal epithelium of both eyes 
was removed under topical anesthesia with a Gill 
corneal knife, with saline subsequently administ-
ered in one eye and MDM in the contralateral eye. 
In the latter experiments an aspirin suppository 
was given to the rabbit 1 hour prior to topical 
application of MDM. 
d) Other routes of administration. Oral ad-
ministration was performed via a gastric tube 
inserted into the stomach through the esophagus. 
Suppository administration was achieved using gel-
atin suppositories which were halved and MDM placed 
between the two halves; finger heat was sufficient 
to reseal the suppository. Intravitreal injections 
were made in a 10 ul volume via a Hamilton syringe 
and a 30 guage needle into the center of the 
vitreous as observed through the cornea. The site 
of injection was about 6 mm posterior to the 
limbus. Administration of MDM at concentrations 
of 5, 10 or 25 pg/0.1m1 into the 3rd ventricle of 
rabbits was made as described previously (9,10): 
10P was measured using a floating-tip applanation 
tonometer and body temperature measured with a 
rectal probe. 





was measured by direct femoral artery cannulation, 
using a Sanborn transducer connected to a recorder. 
Blood pressure was measured either continuously 
over 8 hours under urethane anesthesia, or between 
5 and 8 hours after administration of MDM. In the 
latter experiments the animal was conscious for 
the first 5 hours and was subsequently anesthetized 
and cannulated. 
f) Aqueous humor flow rate. 1) Fluorometry: 
Aqueous humor flow rate was determined using 
fluorophotometry (11), using an apparatus similar 
to that described by Waltman and Kaufman (12). 
Fluorescein was administered topically to the 
cornea and the aqueous humor fluorescein concen-
tration was determined at intervals (13) both 
before and after administration of 0.5 mg per 
animal of MDM. 
ii) Inulin dilution: Measurements of aqueous 
humor formation rate and pseudofacility were made 
4 to 6 hours after intravenous injection of MDM in 
the urethane anesthetized rabbit using an inulin 
dilution technique (14). The technique consists 
of perfusion of inulin through an eye in which 
the IOP is held constant at the drug-induced 
pressure and the dilution of inulin is monitored, 
thereby allowing calculations of aqueous formation 
rate. Pseudofacility was determined in a similar 
manner but with the TOP raised by 5 mmHg above the 
drug-induced value. 
g) Aqueous humor protein concentration. One 
hundred pl of aqueous humor was removed from the 
eyes of rabbits at either 1 or 6 hours after admin-
istration of MDM. Protein determinations were 
made using the Lowry technique (15). 
Rhesus monkeys. Conscious rhesus monkeys (3 kg) 
were placed into restraining chairs specifically 
designed to allow measurements of TOP was measured 
at 0, 1, 3 and 6 hours with drug administration 
made after the 1 hour reading. The chair is 
designed to tilt and hold the monkeys in a supine 
position for tonography. Control series were run 
at various times during the entire study using the 
same monkeys. A calibrated Alcon Pneumotonograph 
was used for IOP and total outflow facility mea-
surements (tonography was performed with a 10 g 
weight); the latter were performed immediately 
following the TOP measurements. MDM was either 
given intravenously, or topically in eyes in 
which the cornea had been partially scraped. At 
the end of all procedures neosporin ointment was 




a) IOP determination. Since preliminary data 
(8) indicated that the crude water extract was in-
active when applied topically to rabbit eyes, but 
caused a marked fall in TOP when given intraven-
ously, all tests reported in this section were 
performed with intravenous injection. 
A dose related fall in both albino and pigmented 
rabbit IOP was found following intravenous in-
jection of the Soxhlet extracted MDM (Table 1). 
Concentrations as low as 0.005 mg/animal (approx. 
0.002 mg/kg) were effective in significantly re-
ducing TOP. Characteristic of high concentrations, 
but not revealed by the statistical analysis in 
Table 1, is an increase in IOP at 1 or 2 hours 
after injection. Since the hypertensive phase 
occurs at different times in different individual 
animals this phase is not always noted in a group 
analysis (Table 1), although in some cases (see 
Tables 2 and 3) the hypertensive phase is revealed. 
At even higher doses several reactions were seen: 
the animals became listless and completely flaccid 
at either 2 or 5 mg/animal, which with the latter 
dose lasted for up to 3 or 4 days (with a lower 
IOP for about 2/3rds of this time), and the urine 
output of the animals was significantly decreased. 
Repeated daily injections of 0.5 mg/animal of 
MDM showed the characteristic IOP fall in TOP on 
day l;on the next 4 successive days no IOP change 
was seen. Thus, a tachyphylaxis was found to 
repeated MDM administration. This was also found 
when 0.01 mg/animal was given on day 1 and 0.1 mg/ 
animal was given in successive days. 
Previously boiled MDM failed to induce a sign-
ificant fall in IOP, indicating its sensitivity 
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5 6 7 24 
9.6* 7.2* 7.4* 17.8 
+0.6 +0.6 +0.5 +0.7 
-51.7* -64.2* -62.7* -11.9* 
+4.0 +3.2 +2.9 +3.0 
-40.4* -47.3* -48.0* 
+3.3 +3.6 +4.0 
-48.3* -58.8* -65.8* -5.3 
+4.6 +4.1 +1.0 +7.2 
-24.6* -21.4* -26.7* -6.2 
+5.8 +1.8 +5.2 +3.5 
-3.7 -10.8 -10.7 
+2.7 +3.5 +3.6 
+2.0 +0.1 +1.8 +6.9 











0 1 2 3 
1 6 20.4+ 22.4 19.9 
+0.5 +1.7 +71. 46 +1.9 
+17.8* -12.3 +0.6 
+9.7 +8.8 +11.2 
0.1 6 19.8 1 + 2.1 -18.4* -30.5* 
+0.2 +10.4 +4.5 +6.0 
0.01 6 23.4+ -12.9* +6.2 -14.6 
+0.4 +2.4 +8.3 +7.6 
0.005 5 24.6+ -7.4* -22.1* -28.6* 
+1.0 +3.8 +4.0 +5.5 
0.001 6 21.6+ -2.6* -6.3 
1 +0.4 +2.1 +1.6 --2: 1- 
0.0001 6 21.5+ -14.2+ -8.3 -1.1 
+0.6 +3.6 +1.4 +1.5 
1 (boiled) 6 20.4+ -4.2 -8.4 -7.9 
+0.6 +2.4 +2.3 +2.7 
Values are the mean + SEM, n, number of animals. +, absolute values of 1OP in mmHg, 
* values given as percentage of original IOP; -, indicates fall, +, indicates increase 
in IOP. All 0 time values are mean IOP + SEM. The difference between the decrease in 
absolute IOP and the percentage IOP is that each percentage fall represents the mean 
calculated for each eye and its base line value, whereas the absolute IOP's shown are 
the mean of those absolute values. *, significantly different from base-line IOP, 
p < 0.05. 
b) Antagonists. In the determination of 
interaction with adrenergic blocking agents, a 
standard dose of 1 mg or 0.1 mg per animal of MDM 
was used (Table 2). Phenoxybenzamine, 0.5 mg/kg, 
had no effect on either the hyper- or hypotensive 
effect of MDM but 5 mg/kg suppressed the hyperten-
sive effect (Table 2). Propranolol, at the same 
concentrations, caused similar effects. Sotalol 
at either 5 mg/kg, which reduced IOP by about 15-
18% alone, or 0.5 mg/kg which alone reduced IOP by 
10%, had no effect on the hyper- and hypotensive 
drug effects. Phentolamine also had no effect on 
the IOP change induced by MDM (Table 2). Timolol 
at 0.5% given topically at every hour did not 
block the IOP-lowering effects of MDM. Indometha-
cin blocked the hypertensive IOP phase induced by 
MDM but had no effect on the hypotensive phase 
(Table 3). Hexamethonium chloride, injected at 6 
hours after the administration of MDM, had no 
effect on the hypotensive IOP phase. Pretreatment 
with tripelennamine also had no effect on the IOP 
pattern caused by MDM (Table 3). Unilaterally 
ganglionectomized rabbits showed a similar pattern 
of IOP change in both eyes following intravenous 
administration of 0.2 mg/animal of MDM (Table 3). 
c) Topical administration. Topical adminis-
tration of MDM on an intact cornea was ineffective 
is causing a change in IOP. Various concentrations 
were used (up to 10%)in the presence and absence of 
benzalkonium chloride (0.04%) and cetylpyridinium 
chloride (0.02%). Since no effect was found under 








































Table 2: Effect of adrenergic antagonists on the TOP fall induced by marihuana-derived 
materia:. 
Drug and 
Concentration n Time (hours) 
1 2 3 4 5 6 
Phenoxybenzamine 3 -6.5 +35.7* +13.7 -24.8* -31.8* -37.3* 
(0.5 mg/kg) +3.8 +14.1 +7.3 +6.2 +3.8 +5.0 
Phenoxybenzamine 3 -11.2 -17.7 -13.7 -40.8* -50.0* -54.5* 
(5 mg/kg) +5.2 +9.2 +6.5 +5.7 +2.0 +3.1 
Phenoxybenzamine 2 -11.5 -23.0* -14.0 -23.0* -18.0* -24.5* 
alone (5 mg/kg) + 0.5 +2.0 +3.0 +2.0 +2.0 +3.5 
Phentolamine 6 -6.0 -5.0 +2.5 -13.6 -43.8* -51.7* 
(0.5 mg/kg) +2.2 +4.2 +8.2 +3.9 +2.4 +2.4 
Phentolamine alone 4 -14.9* -9.1 -6.6 -10.6 -7.8 -2.4 
(0.5 mg/kg) +2.7 +1.8 +2.7 +3.9 +3.2 +2.1 
Propranolol 8 -4.5 +13.8 +5.2 -9.9 -34.9* -45.8* 
(0.5 mg/kg) +1.8 +5•.9 +5.7 +8.7 +3.7 +3.6 
Propranolol 6 -7.3 -2.6 -7.8 -20.7 -41.2* -48.6* 
(5 mg/kg) +2.1 +2.6 +8.6 + 6.7 +3.9 +4.8 
Propranolol alone 5 -5.6 -7.5 -6.5 -6.7 -9.3 -6.5 
(5 mg/kg) +1.6 +1.8 +2.8 +2.5 +3.9 +3.5 
Propranolol alone 5 -4.2 -4.1 -7.4 -6.7 -4.2 -5.2 
(0.5 mg/kg) +3.8 +1.2 +1.0 +3.2 +2.6 +1.5 
Sotalol 6 -11.2 +3.4 +3.9 -10.0 -16.2 -45.1* 
(0.5 mg/kg) +3.2 +6.1 +6.8 +5.1 +6.1 +2 7 _ 	. 
Sotalol 8 -14.9 +38.8* +7.6 -14.3 -28.1* -44.3* 
(5 mg/kg) +2.5 t 8.7 +6.3 +3.6 +7.0 +4.7 
Sotalol alone 6 -12.4 -9.3 -13.8 -14.4 -12.7 -17.6* 
(5 mg/kg) +3.7 +3.8 _ +2.5 +5.5 +3.4 +4.3 
Timolol 	T-1- 5 +0.1 +8.2 +2.7 +8.8 -8.3 -24.9* 
(0.5% topical) UT+ +1.2 +4.1 _ +6.0 +4.5 +4.9 +6.6 
UT-1- 5 +4.1 +6.0 -0.1 +19.3 -3.2 -19.9* 
+5.7 +2.6 +12.4 +11.6 +6.7 +8.1 
Timolol alone 	ri- 3 -10.9 -5.2 -10.9 -6.0 -11.5 -9.6 
(0.5% topical) +3.9 _ +2.1 +3.0 +2.4 + 6.1 +3.0 
UT+ 3 -8.6 -7.9 -7.9 +0.2 +9.1 -4.9 
+4.9 +7.7 +2.0 +2.2 +9.8 +4.7 
All values are the mean + SEM of the percentage change in IOP from the base- 
line readings, established as described in the text. n, number of animals. All 
drug interactions in this table were made using 1 mg MDM per animal. The 
initial 70P of each group was about 20 mmHg (see Table 1). *, significantly 
different from base-line TOP, p < 0.05. +, T treated, UT untreated, since 





Table 3: 	Effect of various antagonists on the IOP fall induced by marihuana-derived material. 
Drug and 
Concentration Time (hours) 
1 2 3 4 5 6 7 24 
Indomethacin 5 -5.6 -9.8 -18.0* -19.2* -35.3* -46.8* -39.2* -1.3 
(20 mg/kg) +5.3 +5.6 +3.3 +2.6 +2.8 +3.4 +3.2 +3.3 
Indomethacin alone 5 -12.0 -12.3* -5.0 -8.8 -4.6 -7.3 -5.3 -3.1 
(20 mg/kg) +3.4 +2.6 +2.6 +4.2 +2.5 +4.3 +4.7 +2.7 
Tripelennamine* 4 +28.2* +19.5 -23.1* -32.6* -40.2* -43.8* 
(4 mg/animal) +5.6 +8.5 +3.1 +1.9 +4.0 +2.1 
Tripelennamine alone 6 +0.2 +3.7 -0.8 -5.9 -5.4 -7.5 -4.1 +0.8 
(4 mg/animal) +2.4 +2.5 +2.0 +2.8 +2.8 +2.8 +2.5 +2 . 8 
Tripelennamine* 4 +21.5* +45.6* +3.7 -21.0* -36.7* -47.1* 
(2 mg/animal) +3.4 +13.4 +4.2 +1.6 +3.4 +4.7 
Tripelennamine+ 4 -3.8 -2.0 -5.5 -27.1* -29.6* -41.0* -52.7* -35.6* 
(18 mg/animal) +2.4 +4.4 +6.8 +9.5 +8.4 +8.2 +5.1 +2.2 
Tripelennamine alone+ 3 -6.2 -9.4 -14.5 -16.3 -9.0 -13.3 -12.7 -3.9 
(18 mg/animal) +2.6 +2.1 +2.4 +4.2 +2.4 +3.2 +2.3 +1.2 
Ganglionectomized 6 +26.9* +13.7 -17.7 -33.1* -48.5* -54.7* -51.3* -21.1* 
eyes +6.5 +15.3 +7.2 +5.7 +3.8 +2.7 +3.2 +4.5 
Paired 6 -0.2 +3.8 -16.5 -25.5* -43.1* -52.0* -53.6* -19.8* 



















All values are the mean + SEM of the percentage change in IOP from the base line readings, 
established as described in the text. n, number of animals. All drug interactions shown in 
this Table were made with 1 mg MDM per animal except where indicated by where only 0.2 mg/ 
animal was used. The initial IOP of each group was about 20 mmHg (cf Table 1). *, significantly 
different from base-line IOP, p < 0.05. All antagonists were given intravenously except + 
where subcutaneous injections were used. 
was of high molecular weight (>12,000 daltons), the 
epithelium was scraped off in an attempt to allow 
intraocular penetration. Scraping of the rabbit 
cornea causes the release of intraocular prostag-
landins, thus animals were pretreated with 600 mg 
suppository aspirin 1 hour prior to corneal epith-
elial removal and subsequent administration of 
solutions of various concentrations of MDM. The IOP 
was unaffected by aspirin alone, and topical appli-
cations of MDM were also without effect. 
d) Other routes of administration. Intravitreal 
injection of 1.0 mg of MDM produced a fall in IOP at 
the 24 hour reading which lasted up to 54 hours (the  
maximum time followed). At 24 hours the eyes re-
ceiving MDM were all inflamed and by 48 hours the 
corneas were opaque. Lower concentrations (0.1 and 
0.01 mg) also caused a large unilateral fall in IOP 
which was accompanied by a proteinaceous exudate 
which entered the anterior chamber through the 
pupil. With these lower concentrations, however, 
the eye cleared in 3-4 days although the TOP only 
returned to normal after 5 days. The paired control 
eyes, which received the same volume of saline as 
the experimental eyes, showed only a normal change 
in IOP (ie a fall over 24 hours of about 6%) with 
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Neither gastric nor suppository administration 
of MDM had any effect on IOP. Oral doses as high 
as 25 mg were used, and, to eliminate any acid 
effect MDM was held at a pH of 1.2 for 1 hour prior 
to neutralization and subsequent gastric adminis-
tration. The latter procedure also produced no 
IOP effect. A similar acid )retreatment of MDM 
did, following neutralization, produce an IOP fall 
indistinguishable from normal after intravenous 
injection. Suppository administration of 10 mg 
MDM/animal also induced no effect on IOP. Intra-
ventricular administration of 5, 10 or 25 pg had 
no effect on IOP or body temperature. 
e) Blood pressure. The systemic blood pres-
sure, when measured by either of the two procedures 
used, was unaffected up to 7 hours after adminis-
tration of 0.2 mg MDM/animal. The data obtained 
with constant monitoring of blood pressure, with 
the rabbit under urethane anesthesia, showed a 
gradual fall with time which is to be expected 
with the anesthetic alone(mean blood pressure: 
treated animals, 0 time, 110 + 12 mmHg, and at 6 
hours, 88 + 10 mmHg, n = 4; controls, 0 time, 
115 + 9 mmHg and at 6 hours 90 + 8 mmHg, n = 3). 
Measurement of blood pressure between 5 and 8 
hours after intravenous injection of MDM also 
revealed no effect (treated animals, 8 hours, 
95 + 10 mmHg, n = 3; controls at 8 hours, 98 + 8 
mmHg, n = 3). 
f) Aqueous humor flow rate. i) Fluorophoto-
metry: Aqueous humor flow rates were measured 
fluorophotometrically following the intravenous 
administration of 0.5 rg MDM per rabbit. The data 
are shown in Fig. 1. The aqueous flow rate de-
creased dramatically from control levels, reaching 
a minimum at about 8.75 hours; this decrease 
correlated well with the fall and time course of 
the IOP change. The maximal fall in flow rate 
was to about 20% of the original base-line value. 
ii) Inulin dilution: The aqueous humor form-
ation rate, measured 6 hours after intravenous 
administration of 0.2 mg MDM/animal, when the IOP 
was 8.5 + 0.8 mmHg, was 1.8 pl/min (n=6) 
approximately a 40% reduction from the control 
values of 2.8 p1/min (14). Pseudofacility was 
Fig. 1 Aqueous humor flow rate as a function of 
time after intravenous administration of marihuana-
derived material. 
Values are the mean + SD of 7 rabbits. 
0.04 + 0.01P1/min/mmHg (n=6) which was unchanged 
from the control value of 0.06 + 0.01 ul/min/mmHg. 
g) Aqueous humor protein concentration. The 
protein content of aqueous humor was measured in 
animals receiving 1.0 mg MDM and the results are 
shown in Table 4. It is evident that the protein 
concentration is increased during the initial 
hypertensive phase and continues to increase 
during the hypotensive phase. 
Rhesus monkeys. Intravenous injections of MDM in 
rhesus monkeys revealed no change in IOP even at 
concentrations as high as 20 mg per animal (app-
roximately 6 or 7 mg/kg). Initial experiments were 
made with low concentrations (0.2 mg/animal) and 
MDM was injected via a syringe with a Millipore 
cellulose filter attached. Following the failure 
to induce an effect at 0.2 mg/monkey, correspond-
ing injections were made in rabbits to ensure that 
the MDM was still active after passage through the 
filter. A solution was made at a concentration of 
0.2 mg/ml and one series of 4 rabbits was injected 
with unfiltered MDM while another 4 rabbits re-
ceived injections with a Millipore filter on the 
syringe. A 50% decrease in activity was found 
between filtered versus unfiltered MDM. Unfiltered 





Table 4: Protein concentration of aqueous humor after intravenous injection 
of marihuana-derived material. 
Time 
	
Protein concentration 	 IOP 










681 + 73* 
	





1245 + 147* 
	 -46.5 + 13.9* 
	
4 
n, number of eyes; *, significantly different from zero time values. 
saline) but still revealed no effect on IOP or 
behavior. 
Topical administration into monkeys eyes which 
had been partially denuded of corneal epithelium 
also revealed no change in TOP either in the pre-
sence or absence of benzalkonium chloride. The 
latter was included in an attempt to enhance the 
transcorneal penetration of the large molecule. 
DISCUSSION 
The isolation of water soluble biologically 
active compounds from Cannabis sativa is not novel 
(5,6), but the finding of water soluble material, 
which can be easily prepared from the raw material 
(16) and which has activity in reducing IOP is a 
new observation. The data appear different from 
the observations of West and Lockhart (7) in 
several aspects, primary of which is the solvent; 
West and Lockhart did not specify their solvent 
thus direct comparisons are difficult. Unlike 
their preparation which was tested in dogs and man, 
however, neither the crude material extract nor 
the more purified material we prepared had any 
activity when applied topically to the rabbit or 
primate cornea (8,16). The material prepared by 
Soxhlet extraction also produced a greater fall in 
IOP (Table 1) than that seen by West and Lockhart 
(7) although differences in the route of adminis-
tration exist. 
As our studies are progressing newer methods of 
preparation and isolation of biologically active  
compounds are being identified, including the use 
of dialysis of the crude water-extract which 
generates a material having similar biological 
activity as described in the present paper (8,16). 
The MDM used in the present study is not a single 
chemical species but a mixture, since it yields 
further subfractions following chromatography, 
which are active in reducing TOP (Deutsch and 
Zalkow, unpublished data). The MDM used was of 
high molecular weight (>12000 daltons) and contains 
a considerable amount of protein and carbohydrate 
(16). 
The present studies have shown that a dose-
related fall in IOP occurs when the MDM is given 
intravenously (Table 1), with concentrations as 
low as 0.005 mg/animal inducing effects which last 
as long as 15 hours. At high concentrations a 
general relaxation and antidiuresis is seen in 
the rabbit. The dose-response curve is the same 
in albino as in pigmented rabbits, indicating that 
there appears to be no discernible effect of 
melanin on the pharmacokinetics of MDM. The MDM 
is also quite stable at room temperature, since a 
solution, tested initially, showed a similar IOP 
activity after 3 weeks of storage. 
High concentrations also elicit a two phase 
change in IOP, an initial hypertensive phase pre-
ceding a profound hypotensive phase, whereas 
lower doses only elicit the hypotensive phase. 
Tachyphylaxis was found to repeated systemic ad-





itial dose was 0.01 mg/animal and successive doses 
of 0.1 mg/animal were given. Whether this is 
caused by the protein moeity of the MDM remains to 
be determined. The proteinaceous nature of the 
MDM is also seen following intravitreal injection 
of 1 mg, where an inflammatory response is noted 
after 36 hours. Lower concentrations also caused 
a proteinaceous aqueous humor to be found but the 
overall response was much less violent. 
The initial hypertensive IOP change resembles 
that seen after prostaglandin (PG) release in, 
or topical application to, the eye (17-19). 
While PG's also cause a hypotensive IOP effect, 
the reduction is not as dramatic as found with 
the present MDM since the maximal fall in IOP 
after PG's was about 7 mmHg (to about 12 or 13 
mmHg); in the present studies the maxima]. IOP fall 
was about 13 or 15 mmHg (to about 6 or 7 mmHg) or 
to values approximating episcleral venous pressure 
(20). 
The antagonists alone had little effect on TOP. 
Phenoxybenzamine alone at 5 mg/kg caused a 25% 
fall in TOP between 4 and 7 hours but had no effect 
on the hypotensive effect of MDM (Table 2). The 
variability of the initial hypertensive phase 
provided some initial variability in the responses 
seen at the 1st, 2nd or 3rd hour but overall it 
appears that the adrenergic antagonists decrease 
the initial hypertensive response when used at 5 
mg/kg (Table 2, compare low and high antagonist 
concentrations). This is adjudged from a consid-
eration of the time-response profile of each 
individual animal and may be related to the TOP-
reducing effects of the antagonists following 
intravenous injection (21). More certain is the 
lack of effect of these agents on the hypotensive 
effects of MDM. Topically applied timolol (0.5%) 
also had no effect on the IOP reduction induced 
by MDM, even when applied 1 hour before MDM and 
every hour thereafter up to 8 hours. The hourly 
regimen was chosen since it has been shown, in 
the rabbit, that timolcl inhibition of isoproter-
enol-stimulated cAMP production by the iris-
ciliary body was at a maximum at 30 min and de-
creased rapidly (22). Hexamethonium chloride, a 
ganglionic blocking agent, given at 6 hours after 
MDM was also without effect, and the response in 
the unilaterally ganglionectomized animals was 
identical in both the denervated and the contra-
lateral normal eye. The data indicate that the 
ocular response to MDM does not occur through the 
adrenergic nervous system (Tables 2 and 3). 
Indomethacin clearly inhibited the initial 
hypertensive response suggesting that a prosta-
glandin or related compound (23) participates in 
at least this phase of the response (Table 3). 
The hypotensive TOP effect and its time-course, 
is however, unaffected by indomethacin. That 
histamine is not involved was shown by the use of 
tripelennamine, which was without effect on either 
phase of the IOP change. 
Topical administration of MDM to the normal eye 
revealed no effect on TOP due to the combination 
of the large molecular size, its water solubility 
and the permeability of, and lipid nature of, the 
epithelium. Even in eyes in which the epithelium 
had been removed no effect was seen. Neither 
intravenous administration to the monkey of as 
much as 20 mg/3 kg animal nor topical administrat-
ion in the deepithelialized eye induced any TOP 
effect. The latter may reflect poor transcorneal 
penetration of this large molecule. The blood-
aqueous barrier of the monkey eye is far less 
permeable to large molecular weight species than 
the rabbit eye, as would be anticipated from 
measurements of osmotic water permeability (24,25) 
and may explain the lack of effect in the monkey 
compared to the rabbit after intravenous adminis-
tration. The intraocular penetration of MDM into 
the rabbit eye from circulation compared to that 
of the monkey may also be related to the involve-
ment of prostaglandins, which break down the blood 
aqueous barrier in rabbit but have a much lesser 
role in the primate. The lack of response when 
MDM was given orally or by suppository must also 
be related to its high molecular weight and fail-
ure to cross the intestinal permeability barrier. 
Intraventricular administration was also without 
effect on TOP or body temperature. 





against the IOP response being mediated by a 
systemic change. Since one of the side effects 
of high concentrations of MDM was an antidiuresis, 
antiogensin II was tested for its effects on IOP. 
Angiotensin has been shown in reduce IOP in the 
cat (26), but no effect was found in the rabbit 
at either 0.0025 or 0.005 mg/animal. 
That the reduction in IOP is caused by a marked 
fall in aqueous humor flow rate, as determined by 
fluorophotometry is evident from Fig. 1. The 
reduction in aqueous humor flow rate correlates 
well with the fall in TOP with minima in both at 
about 9 hours after intravenous injection. Mea-
surements by the inulin-dilution technique showed 
a 401 reduction in aqueous humor formation at 6 
hours after intravenous injection of MDM which 
correlated with the fluorescein data. The under-
lying mechanism of the reduction in aqueous humor 
production is under investigation. The low rate 
of aqueous production, leading to the low IOP, may 
be partly responsible for the increase in aqueous 
protein content, although an increase is found 
during the initial hypertensive phase which may 
be PG-mediated. 
Studies are being undertaken to determine which 
components of MDM are essential for its TOP-
reducing effects. This is particularly pertinent 
in view of its profound effect in reducing IOP, 
since its large molecular weight predisposes 
against topical application. If only a small 
portion of the molecule is needed to elicit the 
response in IOP, then the material, or compounds 
derived from it, may be of potential clinical use 
in reducing IOP. The latter is only possible if 
the problem of tachyphylaxis is overcome, which 
could occur if the molecule can be made considably 
smaller and the protein moeity altered. A smaller 
molecule would also have greater potential for 
transepithelial and transcorneal penetration. As 
a research tool the water soluble Cannabis  
material is of interest due to its effect on 
aqueous humor inflow pathways and the possible 
identification of underlying mechanisms. 
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ABSTRACT 
Further studies have been made with water 
soluble marihuana-derived material (MDM). Neither 
adrenergic, cholinergic, aldosterone, dopamine or 
serotonin antagonism affected the fall in 
intraocular pressure induced by MDM. Partial 
blockade was obtained with galactose, glucose, or 
mannose, but not arabinose, when the latter were 
given at intravenous concentrations of 1 gm/animal 
and MDM was given at 25 pg animal, suggesting that 
these sugars may be involved at the active site of 
the MDM glycoproteins. Dexamethasone was without 
effect on either intravenous or intravitreal MDM 
indicating that the MDM effect is not a 
non-specific response to a protein. A similar 
plant glycoprotein, larch arabinogalactan, at 200 
µg/animal was without effect on intraocular 
pressure. Aqueous humor flow rate was increased 3 
hours after MDM administration, a period 
corresponding to the intraocular pressure increase 
caused by MDM, and fell to 20% of control values 
when the fall in intraocular pressure occurred. 
Blood flow through the irks was increased at both 
one and six hours after intravenous MDM injection 
indicating a vasodilation which could contribute 
to the initial increase In intraocular pressure. 
Intravitreal injection of MDM in rabbit and rhesus 
monkey caused a fall in intraocular pressure only 
after a 24 hour delay: the unilateral response 
indicated that systemic metabolism was not 
required for activity and the delay was likely 
caused by the diffusion time to the ciliary 
processes from the mid-vitreal injection site. 
The changes in beta-receptors, adenylate cyclase 
and carbonic anhydrase in the ciliary processes 
are minimal indicating a possible vascular 
mechanism of action of MDM. 
INTRODUCTION 
We have previously described the isolation of 
water soluble compounds from marihuana which are 
active in reducing rabbit intraocular pressure 
(1). Extensive testing of this compound against 
several antagonists indicated that rx- and fl-adren-
ergic, prostaglandin, and histamine inhibitors 
were ineffective in altering the marked fall in 
intraocular pressure (10P) found with marihuana-
derived material (MDM) when the latter was given  
intravenously to rabbits (2). 	MDM was also 
unaffected by superior cervical ganglionectomy and 
was ineffective when given intravenously to rhesus 
monkeys. It remained to be determined, therefore, 
whether intrinsic pharmacological activity existed 
in the primate and whether the 1OP response could 
be blocked in the rabbit in order to determine the 
mechanism of action of MDM. 
Although these initial studies (1) provided 
some indication of the effects of MDM both in the 
eye and systemically, many questions remained 
concerning the mechanism of action. Since MDM has 
been identified as a glycoprotein (1), an approach 
which has proven effective in identifying the 
mechanism of action of other plant glycoproteins 
(3-5) was used in an attempt to make the same 
characterization of the present compounds. Add-
itional studies have been made to establish the 
time course of the change in aqueous humor inflow. 
MATERIALS AND METHODS 
Drug preparation  
Water soluble marihuana-derived material (MDM) 
was prepared as described previously (1,2) and 
made up fresh for each experiment in 0.9% saline. 
For intravenous injection 1 ml was used and for 
intravitreal injections the volume was 10 p l., the 
latter administered via a Gilman microliter 
syringe. 
Animal testing  
Rabbits. a) TOP measurements. Albino rabbits 
(2-3 kg) were restrained in canvas bags tied at 
the neck and the TOP measured with a calibrated 
Alcon Pneumatonograph. IOP was determined at -40 
min, -30 min, 0 min, and at each succesive hour up 
to 7 hours on each test day. The -40 min reading 





was discarded and the -30 and 0 min values aver-
aged to provide a time-zero value for each rabbit. 
b) Antagonists. Cholinergic antagonists were 
atropine and scopolamine, with each administered 
as 1 drop of a 1% solution 1 hour before MDM 
administration. Other antagonists used were given 
intravenously: haloperidol lactate (dopaminergic 
antagonist) at a concentration of 2 mg/kg (6); 
methysergide (serotonin antagonist) at 5 mg/kg 
(7); 	chlorpromazine 	(adrenergic, 	cholinergic, 
serotoninergic and dopaminergic antagonist) at 1 
and 10 mg/kg (8), spironolactone (aldosterone 
antagonist) at a concentration of 10 mg/kg (9), 
and yohimbine ( u2-antagonist) at 1 mg/kg (10). 
c) Sugars. 	The sugars, either arabinose, 
galactose, glucose, or mannose, were injected 
intravenously at a concentration of 1 gram/animal 
1 hour before injection of MDM (3-5). Intraocular 
pressure was measured hourly following the prot-
ocol outlined above. Control animals treated with 
sugar alone were always used in parallel with the 
experimental animals. 
d) Steroid. A 1% solution of dexamethasone 
was applied topically to rabbit eyes at 21 or 3 
hour intervals for 1 or 2 days prior to intra-
venous or intravitreal injection of MDM. 
e) Aqueous flow rate. Aqueous humor flow rate 
was determined using fluorophotometry (11), using 
an apparatus similar to that described by Waltman 
and Kaufman (12) attached to a Haag-Streit 360 
slit lamp. Fluorescein (Fluress) was administered 
topically to the cornea every 2 min for 30 min, 3 
hours before fluorescein concentrations were 
measured and 200 pg/ MDM was administered intra-
venously 41/2 hours after the last fluorescein drop 
was given, at a time when both corneal and aqueous 
humor fluorescein concentrations were decreasing 
linearly. Control series were made to establish 
the most efficacious regimen of fluorescein 
application. The following solutions were used; 1 
drop of Fluress (0.25% sodium fluorescein, 0.4% 
sodium benoxinate) every min for 30 min; 1 drop of 
Fluress every 2 min for 30 min; 1 or 5% fluores-
cein (in the presence or absence of 0.02% benzal-
konium chloride) at either 1 drop every 2 or 5 min  
for 15 or 30 min and 10% fluorescein at 1 drop 
every 5 min for either 15 or 30 min. Aqueous 
humor flow rate was calculated using the approach 
of Yablonski et al (13), with a corneal volume of 
80 i t and an aqueous volume of 180 r i. All 
animals were of approximately the same size (2 
kg), thus this approximation allowed estimation of 
aqueous flow rate. 
f) Intravitreal injections. Since intra-
venous injection of MDM was ineffective in rhesus 
monkeys (2), determination of any intrinsic pharm-
acological activity in this species required 
intravitreal injection. Studies were made, there-
fore, in the rabbit to delineate the quantity of 
MDM needed to elicit a response. These studies 
also allowed determination of whether systemic 
metabolism of MDM was needed to provide activity. 
Intravitreal injections were made unilaterally in 
the proptosed, locally anesthetized (tetracaine), 
rabbit eye following establishment of base line 
10P. MDM was injected in various concentrations 
with vehicle injected controls run in parallel. 
Initially, lOP was measured hourly during the 
first 8 hours as well as between 22 and 30 hours 
but as the time course became evident readings 
were only taken at 2 hour intervals on day 1 after 
injection. 
g) Blood flow determination. Regional ocular 
blood flow was measured using radiolabeled (
85
Sr) 
15 r diameter microspheres using standard tech-
niques (14-16). MDM was injected either 1 or 6 
hours prior to blood flow determinations. 
h) Blood pressure. Systemic blood pressure 
was measured by inserting a 22 gauge needle, conn-
ected to a Hewlett-Packard transducer and 
recorder, into the median ear artery under 
Cetacaine 	anesthesia 	(Cetylite 	Industries, 
Pennsauken, N.J.). Measurements were made at 0, 3 
and 6 hours with either MDM or saline alone 
injected immediately after the "0" hour reading. 
i) Plant glycoprotein. 	MDM has been 
characterized as a glycoprotein containing neutral 
sugars, including large amounts of arabinose, and 
protein (1); thus a similar plant glycoprotein, 





intravenously to rabbits at 200 pg/animal. IOP 
was determined as above for MDM alone. 
Rhesus Monkeys. Rhesus monkeys (3 kg) were sed-
ated with ketamine (30 mg) and received 1 drop of 
topical tetracaine prior to intravitreal 
injections of MDM using a 30 gauge needle under 
sterile conditions. The animals were then placed 
into restraining chairs (2, 17), which allowed 
suitable restraint yet the capability of measuring 
both IOP and total outflow facility following 
recovery from the 30-minute sedation period. A 
calibrated Alcon Pneumatonograph was used for both 
IOP and outflow facility determinations; a 10 gram 
weight was used for tonography and the latter was 
measured immediately after TOP measurements. 
RESULTS 
Rabbits. 
a) IOP determinations. A dose response 
curve was generated as previously (2) and 
confirmed using a full spectrum of concentrations. 
Purer compounds have been identified subsequent to 
MDM isolation, some of which are active at concen-
trations as low as 1 pg/animal and which induce  
maximal (60%) falls in IOP at concentrations of 10 
rig/animal. These purer compounds exert the same 
effects as MDM but are more active on a weight for 
weight basis. The data obtained with MDM, 
therefore, reflects that for purer compounds in 
terms of pharmacological activity. Isolation and 
characterization of a pure active compound has not 
yet been made. 
b) Antagonists. None of the antagonists 
used affected the fall in IOP induced by MDM. 
None of the antagonists alone affected TOP, except 
the highest dose (10 mg/kg) chlorpromazine which 
significantly reduced IOP (8). This high dose of 
chlorpromazine lowered IOP to a point where 
further reduction was impossible. The maximal IOP 
fall and the time at which this occurred are shown 
in Table 1, and no change was seen compared to MDM 
alone even with 1 mg/kg chlorpromazine. 
c) Sugars. The data obtained following 
sugar and MDM injection is shown in Table 2. 
Arabinose was ineffective in affecting the fall in 
IOP irrespective of the MDM concentration (25, 50 
or 200 pg/animal). Neither glucose, galactose or 
mannose had any effect on the MDM-induced fall in 
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Concn 	zero zero zero 1% zero 5 	zero 2 	zero 1 zero 10 zero 
	
















0 	19.7 	31.2 	C 20.7 	19.2 	20.3 	11.1 
	
±0.4 	±5.3 ±0.6* 	±7.3* 	1'0.3* ±2.4* 
E 21.3 	15.4 	19.5 	13.7 
±0.6* 	±8.2* 	±0.4* 13.6* 
50 	19.8 	28.4 	C 20.9 	28.4 	20.4 	36.3 
±0.7 	19.3 10.8 ±9.3 	±1.8 	±10.2 
E 21.3 	32.6 	20.7 	43.1 
±0.6 ±2.7 	±1.6 ±6.9 
- 21.1 	4.3 	26.0 	15.7 	24.2 	40.0 	20.9 	19.1 	23.4 	+11.4 
11.8+ ±7.6+ 	±0.3+ ±2.5+ ±0.4+ 	±6.4+ 	±1.6* ±7.4* 	±0.8 	t4.0 
100 	20.1 	47.4 	 20.6 	43.9 	19.3 	43.9 	23.9 	34.6 	19.8 	50.9 
±0.6 	t7.4 ±0.6 	±3.7 ±1.1 	±3.7 	±0.3+ 30.9 	15.8 
200 	20.2 	47.0 	C 19.9 	45.7 	19.8 	57.0 	 22.5 	46.6 	26.2 	45.3 
±0.5 	±6.2 ±0.7 12.0 	±0.6 ±2.0 ±0.5 	14.0 	30.2 ±2.0 
E 20.9 	49.3 	19.8 	56.7 
±0.7 ±6.6 10.8 ±4.6 
The data represent percentage fall in LOP from time zero value (given in mmHg) at 6 hours after MDM administration (or antagonist administration at an 
MDM concentration of 0) was given intravenously. A, atropine; S; scopolamine; M, methysergide, 5mg/kg; H, haloperido1,2mg/kg; C, chlorpromazine, 1 or 
10mg/kg; Sp, spironolactone, 10mg/kg; Y. yohimbine, 1mg/kg. Atropine and scopolamine were given topically; methysergide, haloperidol and chlorpromazine 
were given intravenously. For topically administered drugs the values are given for both treated eye (E, treated with topical antagonist) and control 
eye (C, non-antagonist treated). All values are the mean ± SEM of 6 animals except where indicated, *, n=3, +, n=4. No fall in IOP after antagonist 




















0 - - 21.2 8.7 28.1 7.5 28.9 4.3 26.9 +1.5 
10.9(4) ±3.3(4) ±0.3(4) ±3.5(4) ±0.8(4) ±1.2(4) ±0.8(4) ±5.1(4) 
25 19.7 31.2 18.9 33.9 20.3 22.6 21.2 21.2 20.4 18.2 
±0.4(6) ±5.3(6) ±0.7(6) ±3.1(6) ±0.9(6) ±3.6(6)* ±0.6(6) ±3.0(6)* 10.4(6) ±3.0(6)* 
50 19.8 28.4 17.2 43.5 18.2 34.1 21.0 30.2 16.7 33.1 
'10.7(6) ±9.3(6) ±0.5(6) 14.2(6) ±0.4(4) 13.3(4) ±0.2(4) 1'5.1(4) ±0.8(4) ±5.0(4) 
100 20.1 47.4 21.7 40.0 - 
±0.6(6) ±7.4(6) ±0.8(4) ±6.2(4) 
200 20.2 47.0 24.1 50.9 24.4 46.2 24.6 49.9 22.2 52.4 
±0.5(6) ±6.2(6) ±0.3(6) ±2.5(6) '10.5(6) 03.4(6) ±0.4(6) ±3.4(6) ±1.9(6) ±2.7(6) 
The numbers represent the mean ± SEM of the percentage fall in IOP 6 hours after the time zero value (given in mmHg). 
The numbers in parenthesis are the numbers of animals. *, P < 0.05 compared to "no sugar" data. 
Table 3, Effect of dexamethasone on LOP after MDM in rabbit. 
MDM concentration 
(ug) 





fall in 10P 
Time of maximal 


























20.1 	± 0.5 
20.1 ± 0.9 
21.8 ± 1.3 
21.8 	± 	1.1 
19.8 ± 0.4 
20.0 ± 0.8 
21.9 	± 	0.1 
19.1 	± 	1.1 
21.6 	± 0.7 
20.3 ± 	1.1 
33.9 	± 	2.2 
34.0 ± 4.1 
32.3 	± 4.1 
34.2 	± 	4.4 
35.4 ± 3.2 
35.2 ± 4.2 
16.6 	± 	4.0 
17.0 ±10.8 
41.6 ± 6.8 











Paired eyes were either T, treated with steroid; or N, not treated with steroid. Fall in 10P is the 
maximal percentage fall from the time zero value (given in mmHg) at the time shown. MDM concentration 
of 0 was saline control. All values are the mean ± SEM of the percentage fall in 10P. For 
intravitreal injections, both eyes were treated with steroid and only one (E) received MDM while the 
other (C) was the control eye. n, number of rabbits. * indicates significantly different from paired 
eye, p < .01. 
LOP at MDM concentrations at or above 50 Fg/ 
animal. At 25 fig MDM/animal, however, galactose, 
glucose and mannose induced partial blockade at 
the MDM-induced fall in TOP. 
d) Steroid. 	Dexamethasone pre-treatment 
alone caused only a slight (16%) fall in IOP. 
When MDM was given intravenously (Table 3) the 
fall in IOP was similar in both non-treated and 
steroid-pretreated eyes, and the fall in IOP in 
both eyes was similar to that seen in the absence 
of steroid. Intravitreal injection of MDM was 
also unaffected by steroid pretreatment (compare 
line 5 of Table 3 with Table 4). 
e) Aqueous humor flow rate. The rate of 
aqueous humor flow was calculated after various 
regimens of fluorescein application. The most 
effective regimen was 1 drop of Fluress applied 
every 2 min for 30 min; other regimens and 
solutions did not provide as high a corneal or 
aqueous fluorescein concentration. 
The aqueous flow rate is shown in Fig. 
indicating that the flow rate remains virtually 
unchanged over the first 2 hours after intravenous 
injection of 100 pg MDM/animal before increasing 
by about 30% at 3 hours. This increase was not 








































C 	7.1 	± 8.3 
E +1.7 	± 0.5 
C 	8.9 	± 	2.9 
E 	6.3 ± 8.7 
C 11.5 t 7.8 
E 	6.2 t 3.6 
C 	7.9 ± 7.5 




























24 	 26 
	
28 	 30 
± 3.5 	4.7 ± 1.2 	13.9 t 3.3 	16.2 ± 8.0 	8.1 ± 4.6 
± 0.5 	9.6 ± 0.7 17.5 ± 2.6 	20.7 t 0.6 	6.4 ± 10.8 
± 4.1 	01.5 ± 22.0 	0.2 ± 15.7 	1.2 ± 16.3 	8.8 ± 21.2 
± 8.4 	27.9 ± 8.6* 	38.1 ± 8.4* 	36.7 ± 8.0* 38.6 ± 13.1* 
± 8.7 	15.3 ± 5.9 	8.2 ± 8.1 	12.6 ± 1.8 	13.9 ± 3.9 
± 5.6 	51.6 ± 6.1* 	47.8 ± 5.3* 	50.2 ± 4.9* 52.8 t 3.5* 
± 6.2 	6.7 ± 5.3 	1.0 ± 6.4 	10.0 1. 7.8 	6.3 ± 5.0 
± 3.2 	43.7 t 4.3* 	52.5 1 1.3* 	50.7 ± 1.5* 43.8 ± 2.8* 
MDM concentration (pg/eye) injected intravitreally in 10 pl. Values given are mean ± SEM of percentage fall in IOP from the time 
zero value (except where a + precedes the value, when this indicates an increase in 'OP). Time-zero 100 value in mmHg. Time is 
hours after injection. C, non-injected eye; E, injected eye. Vehicle alone was used when MDM was 0. * indicates significantly 


























0 1 	2 	3 	4 	5 
Time (hours) 
 
Aqueous humor flow rate as a function of time 
after intravenous MDM administration. 
Values are the mean ± SEM of 6 animals (12 
eyes) at each time shown. 
then decreased markedly 	to a statistically 
significant maximal fall of 80% between 5 and 7 
hours. This fall in flow rate correlated with the 
IOP at this time (14.2 ± 0.8 mmHg at 5 hrs after 
MDM, p .01 compared to time zero value). The 
increased flow rate at 3 hours appears to be 
correlated with the already documented increase in 
IOP seen at a similar time after the 
administration of at least 100 jig MDM (2). 
f) Intravitreal injections. The data obtained 
after intravitreal injection of MDM is shown in 
Table 4. Little change in TOP was found during 
the first 22-24 hours, but thereafter the IOP fell 
rapidly to low levels equivalent to those found 
after intravenous administration except that the 
fall in TOP was unilateral. The magnitude and 
duration of the fall in IOP was dependent upon the 
administered dose. In one group of 6 animals with 
100 jig/eye the IOP was followed for up to 144 
hours and the percentage fall in IOP of the 
injected eye from base line was 33.5 ± 1.2% and in 
the contralateral paired control eye was 4.3 ± 
3.6% at 144 hours, indicating the longevity and 
unilateral nature of the response. 
g) Blood flow determinations. 	The data 
indicate that iris blood flow is increased at both 
1 and 6 hours after intravenous MDM, but the flow 
is unchanged in other ocular tissues (Table 5) 
compared to controls. 	The iris vessels were 
substantially dilated and with blood flow being 
the same in other tissues a greater blood flow 
occurred through the whole eye. 
h) Blood pressure. Systemic blood pressure 
was found to decrease during the day in control 
animals by about 14 mmHg (Table 6) and a lesser 
change occurred in MDM-treated rabbits. No change 
was observed in these conscious animals which 
could contribute to the massive fall in IOP after 
MDM. 
i) Plant  glycoprotein. 	Intravenous larch 
arabinogalactan had no effect on rabbit IOP at a 





Table 5: Regional ocular blood flo n rabbit after intravenous MDM. 
Tissue 
	
Blood flow (mg blood/mg tissue/min) 






1.29 t 0.39 
2.37 ± 0.47 
0.39 1 0.08 
3.84 ± 0.84* 
3.67 t 0.69 
0.22 ± 0.05 
3.32 t 0.49* 
3.15 0.28 
0.07 1  0.02* 
Choroid 	 19.83 ± 2.60 	35.86 ± 7.87 22.57 1 2.79 
Values are mean ± SEM for 6 animals in each group. *, P e 0.02. 
Table 6: Rabbit blood pressure after MDM 








73.8 ± 5.8 (6) 
	
63.4 ± 1.9 (15) 
3 
	
62.5 ± 3.5 (6) 
	
53.9 	2.9 (15) 
6 
	
59.8 ± 3.0 (6) 
	
57.4 f 2.0 (13) 
Experimental animals received 100u g MDM after the "0" hour reading 
and control animals received 1 ml saline. Values are the mean ± SEM; 
numbers of animals in parenthesis. 
unlikely that a gross similarity of chemical 
structure or simply an osmotic effect of a large 
molecule in the circulation plays a role in 
reducing IOP. MDM, therefore, appears unique in 
its ability to reduce IOP. 
Rhesus monkeys. 	Intravitreal injection of 
0.01 jig MDM/eye resulted in a rise in 10P for the 
first 24 hours followed by a pronounced fall in 
10P which lasted for approximately 3 days. Inject-
ions of 0.001 jig MDM/eye caused only a fall in IOP 
which was 50% at its maximum at 36 hours, and 
lasted for up to 54 hours. No change in total 
outflow facility occurred during either the rise 
or fall in IOP (Table 7). At neither concentra-
tion was the total outflow facility (mean value 
0.58 1il/min/mmHg) markedly changed. 
DISCUSSION The progressive sub-fractionation of 
MDM has identified a series of compounds which 
appear to be closely related, thus MDM is a mix-
ture rather than a single chemical. As purif-
ication has proceeded, the activity of the mater- 
ials, in terms of IOP-reducing capability per unit 
mass, has increased such that some compounds cause 
a fall in IOP up to 60% with a concentration of 1 
pg/animal (unpublished data). The pharmacological 
profile is unchanged, however, since those more 
purified compounds thus far tested show the same 
action as MDM. Pharmacological data obtained with 
MDM, therefore, is relevant to subsequently 
purified compound(s), although purification of a 
single chemical structure has not been achieved to 
date. 
The experiments reported here concern MDM and 
its collective pharmacological activity. The 
studies with atropine and scopolamine indicate 
that blockade of the cholinergic (muscarinic) 
receptors in the eye has no influence on the time 
course or magnitude of the pressure fall induced 
by MDM. Neither dopaminergic (haloperidol and 
chlorpromazine), adrenergic (yohimbine), 
adrenergic and cholinergic (chlorpromazine) nor 
serotoninergic (methysergide and chlorpromazine) 







Spironolactone, an aldosterone antagonist, was 
also without effect, indicating that the 
mineralocorticoid did not interact with MDM. 
Neither haloperidol nor methysergide alone induced 
a change in IOP, but a high concentration of 
chlorpromazine alone caused a fall in IOP of up to 
30% which lasted for about 6 hours which 
correlates with previous observations (8). 
The studies with preloading of sugars, which 
has proven successful in other studies in ident-
ifying the mechanism of action of active glyco-
proteins (3-5), indicated that mannose, glucose 
and galactose were effective in causing partial 
blockade of the MDM effect of IOP, at least at low 
concentrations of MDM. Arabinose had no effect 
even at low MDM concentrations. Because MDM is a 
mixture it is difficult to assign a particular 
blocking effect to one sugar, and it appears that 
the active components of MDM have either mannose, 
glucose or galactose at a site which contributes 
to the pharmacological activity of MDM. Specific 
glycoproteins of MDM may contain only one of the 
sugar groups but these and other common features 
remain to be identified. 
To determine whether or not the ocular 
hypotensive response was a non-specific 
inflammatory reaction, dexamethasone, a steroid 
known to enter the rabbit aqueous humor with ease 
(18), was administered for 2 days prior to MDM 
injection by either intravenous or intravitreal 
routes. No blockade was found to intravenous or 
intravitreal MDM administration. This confirms 
our previous observation (2) that boiled MDM 
failed to induce an effecyon IOP. The effect on 
IOP appears to be a specific response and not a 
non-specific response to a foreign protein. 
Confirmation of this effect is seen with the 
absence of an inflammatory reaction with low 
concentrations of intravitreal MDM. The 
specificity of the fall in TOP to this particular 
arabinogalactan (MDM) is indicated by the failure 
of the IOP to respond to larch arabinogalactan. 
Aqueous humor flow rate has been determined at 
hourly intervals following the intravenous, but 
not intravitreal, administration of MDM. Previous  
studies (2) began measurements at 5 hours and 
correlation was found between the decrease in 
aqueous humor flow rate and 10P, but the IOP is 
known to increase at early times (1-3 hours) after' 
injection and it was important to determine 
whether or not the aqueous flow rate followed the 
same time course as IOP. The data obtained (Fig. 
1) indicate that the ocular flow rate is virtually 
constant for 2 hrs after MDM administration before 
rapidly increasing by about one third and then 
declining rapidly to about 20% of control values 
at 4 hours through 8 hours. The IOP was recorded 
only at 5 hours in the present experiments and was 
significantly decreased (14.2 ± 0.8 mmHg), but the 
usual pattern of IOP (2) would have been expected 
at the dose of MDM used in these experiments. The 
increase in IOP at 1-3 hours after intravenous MDM 
may be associated with the increase in aqueous 
humor formation, as well as a change in ocular 
blood flow (Table 5). A change in ocular blood 
volume can cause a marked change in TOP (19). 
Dilation of the renal vascular bed has been 
noted in the dog after MDM administration (C.C. 
Bond, personal communication), and it is possible 
that a similar change occurs in the rabbit. The 
blood flow measurements with radiolabeled 
microspheres indicate an initial iris vessel 
dilation at both 1 and 6 hours with other tissues 
showing no change compared to controls. The 
marked suppression of aqueous humor inflow at 
later times could mask any vascular effect on IOP. 
Intravitreal injections of MDM produced a 
markedly different response from that seen after 
intravenous injection. With the latter, the fall 
in TOP occurred within 3 - 4 hours after admin- 
istration but after intravitreal administration 
the fall in IOP was delayed up to a maximum of 24 
hours. The unilateral response observed indicates 
that the effect was not due to systemic metabolism 
but rather a local response within the eye. This 
was reconfirmed by the data obtained after uni- 
lateral intravitreal injection in the rhesus 
monkey (Table 7). The cause of the delay in both 
species, however, remains undetermined at this 
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C 	3 	27.7 
±0.3 
0.001 vg 
E 	3 	32.2 
±2.0 
	
28.7 	31.3 	29.7 	25.7 	27.0 	30.3 	27.7 	25.0 	24.0 
±1.3 	±3.8 	±2.9 	t0.7 	±3.0 	±2.9 	t1.4 	30.6 	±4.0 
30.3 	47.0 	34.2 	20.2 	17.7* 	15.0* 	13.3* 11.7* 	12.0* 
14.7 	33.0 	310.4 	34.9 	11.7 	±5.0 	14.4 	±2.8 	±2.5 
28.7 	27.7 	25.0 	26.3 	29.5 	27.3 	28.7 	26.5 	27.0 
±0.3 	±0.9 	±0.6 	±1.4 	-±1.2 	±1.8 	t1.4 	±1.6 	±1.0 
32.7 	16.7 	16.3 	15.3* 	16.0* 17.3* 16.7* 	15.3* 16.7* 
t1.2 	±6.6 	±6.7 	1:6.7 	±4.9 	17.3 	37.3 	±6.1 	±5.3 
C, control, paired eye; E, experimental, MDM-injected eye; n, number of eyes. Values 
are the mean ± SEM of the absolute IDE in mm Hg. * indicates significantly lower than 
paired eye at any time, p < .05. 
administration of as little as 25 pg MDM/animal, 
or 0.17 fg/m1 plasma, (with the plasma volume of a 
3 kg rabbit being 150 ml) results in a fall in IOP 
with a short delay while the direct intraocular 
injection of MDM has a delay period with an 
ocular penetration, as discussed previously (2) is 
the reason for the difference between this data 
and intravenous administration. The lack of 
effect on total outflow facility indicates that 
the mechanism of action in the primate resembles 
average of about 22 hours. 	Whether this is 	that in the rabbit and that some component of 
related to the distribution of MDM in the eye and 
the time needed to reach a sufficiently high MDM 
concentration at the ciliary processes remains to 
be determined. It is known, however, that a small 
molecule such as sucrose, when injected 
intravitreally takes about 4 to 20 hours (01=15 
hr) before high levels are observed in the aqueous 
humor (20). Thus, anteriorly directed diffusion 
of MDM, a much larger molecule (20,000 - 40,000 
daltons) than sucrose, would be slower and the 
delay in response compared to intravenous MDM 
could be due to the fact that intravascular 
material could reach the ciliary processes much 
earlier than intravitreal MDM. A dose-related 
response occurs to intravitreal MDM, and the 
longevity of the fall in WI) appears related to 
the amount injected. IOP falls as long as 4 days 
were encountered with as little as 1 jig/eye with 
the fall in IOP still being about 48%, and at 3 
days after 0.1 rg/eye an IOP fall of 42% was 
found. 
The rhesus monkey data indicate that MDM has 
pharmacological activity in the primate when given 
intravitreally, and it is most likely that intra- 
aqueous inflow is severly compromised by MDM 
action. 
Preliminary studies indicate that the MDM 
effect is not related to carbonic anhydrase since 
large amounts of MDM (up to 10 mg) had a minimal 
effect on the enzyme (T.H. Maren, personal 
communication), and no change in adenylate cyclase 
(by direct assay with 
32
P-ATP on membrane 
fragments), or increase in responsiveness to 
$-agonists and guanyl nucleotides was found in 
rabbit iris-ciliary body (T.W. Mittag, personal 
communication). Furthermore, neither cerebrospinal 
fluid (CSF) production, nor CSF pressure nor 
arterial pressure in either cats and rabbits are 
affected by MDM given by intraventricular (25 
pg/m1), intraperitoneal (250 .ig/kg) or intravenous 
(1 mg/kg) routes (B.P. Vogh, personal 
communication). All the above experiments used 
MDM concentrations which were well in the range of 
inducing a substantial fall in TOP when given 
intravenously. 
Despite the array of antagonists which have 
been employed (2, and Tables 1, 2 and 3) against 





MDM reduces intraocular pressure by reducing 
aqueous humor formation and whatever component of 
aqueous is affected it is markedly impaired. The 
present data differ from that seen with cholera 
toxin (21) where intravitreal (0.26 lig) and intra-
arterial (2.1 lig) injections cause a decrease in 
net aqueous flow by 50% in 8 hours and doubling of 
blood flow to the anterior uvea at 8 to 13 hours. 
Cholera toxin stimulates adenylate cyclase by 2.2 
-fold and cyclic AMP production by ciliary pro-
cesses by 7.4 times (21). Outflow facility has 
also been found to increase after intravitreal 
cholera toxin (22). MDM does not increase outflow 
facility, does not cause an increase in adenylate 
cyclase, appears to act exclusively on aqueous 
formation, but does decrease IOP by large amounts 
although the time course is quite different from 
that of cholera toxin. 
The mechanism of action may reveal alternative 
pathways by which aqueous humor entry into the eye 
can be modified, and the effect in the primate 
offers the possibility that some component of the 
large molecule may be identified which could be 
capable of inducing a fall in IOP. The absence of 
a change in adenylate cyclase, -receptor response 
or other biochemical indices with MDM, such as 
seen after catecholamine or cholera toxin and 
which reflects an epithelial cellular response to 
these drugs, suggests that, some vascular component 
of aqueous humor inflow is being affected. Such a 
change occurs despite the lack of a large effect 
on measured blood flow, since perhaps some 
previously unidentified regulatory component is 
affected by MDM. Furthermore, the failure of 
known receptor antagonists to affect the response 
induced by MDM suggests that MDM may not be acting 
at a specific recognition site but at another 
locus of action such as a cell membrane or by 
induction of a secondary response. 
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ABSTRACT 
Studies have been made in an attempt to 
elucidate the mode of action of water-soluble 
marihuana-derived material (MDM). MDM lowers 
intraocular pressure (TOP) at systemic dose 
levels greater than 5 pg/rabbit by reducing 
aqueous humor inflow. Blood pressure, body 
temperature, and PO remain constant despite the 
wide variation in TOP caused by high dose levels 
of MDM, viz. an initial hypertensive phase 
followed by a hypotensive phase. Blood PCO 2 and 
pH, however, both decrease with 1 mg MDM/rabbit 
indicating an acidosis which may partially 
explain some of the fall in TOP caused by MDM at 
this high dose level. Low doses of MDM (50 
pg/animal), however, induce no such changes in 
systemic chemistry, illustrating the absence of 
an MDM effect which can explain the greater than 
50% fall in IOP. Repeated injections of MDM on 
a weekly basis indicate a sequentially reduced 
effect on IOP. MDM, when incubated in vitro for 
6 hours with saline, aqueous or vitreous, always 
induced a fall in TOP; incubation in these media 
for 24 hours, however, reduced the capacity to 
induce an TOP decrease. When aqueous or 
vitreous was removed from animals which had 
received intravitreal injections of MDM 24 hours 
previously (thus, at e time when the TOP in 
these animals was low) and was reinjected intra-
vitreally into fresh recipient rabbits, the TOP 
fell in the recipients. with aqueous, but not 
vitreous. Only when high doses of MDM (a 2 mg) 
were given systemically to a donor rabbit was 
any evidence obtained of a fall in TOP in recip-
ient rabbits at short times after the donor 
injection (< 10 min); at greater times after the 
donor injections whole blood or serum from donor 
rabbits failed to elicit a fall in TOP in recip-
ient animals. These data indicate that, in 
vivo, MDM is bound or metabolized rapidly in 
rabbits when MDM is given systemically. 
INTRODUCTION 
It is now well established that either 
intravenously or intravitreally administered 
water-soluble marihuana-derived material (MDM) 
causes a marked reduction in intraocular pres-
sure (TOP) in the rabbit (1,2). In rhesus mon-
keys, effects are only seen after intravitreal 
injections (2). Typical dose levels required to  
induce a fall in TOP of about 50% are: systemi-
cally, 1 to 5 pg/animal (1,3), and intravitreal-
ly, 0.001 to 0.01 1.1g/eye (2). This material, 
which is a high molecular weight glycoprotein 
(ca.5 x 10
5 
daltons) (3,4), is, therefore, 
extremely potent, cannot be blocked by conven-
tional antagonists (2,3), and its mode of action 
remains an enigma. Despite several attempts to 
discern the mechanism by which such a large 
reduction in TOP is induced, it has proven 
impossible to identify either systemic or ocular 
changes which are responsible. 
In a further attempt to identify the processes 
which may impinge on the effects of MDM and to 
further discern its mode of action, a series of 
experiments were performed. These were directed 
at attempts to recover MDM at various times 
after systemic or ocular administration in order 
to determine whether MDM was binding to blood or 
serum constituents and to examine blood gas, as 
well as blood pressure, responses to various 
doses of MDM. 
MATERIALS AND METHODS 
Several types of experiments were performed 
using adult albino rabbits weighing between 2 
and 3 kg. MDM was obtained from Mexican mari-
huana, supplied by the University of Mississippi 
Research Institute for Pharmaceutical Sciences 
under the auspices of the National Institute on 
Drug Abuse. Portions of leaves and small stems 
were macerated in a Waring blender with warm 
water (55-60 ° ), the resultant liquid filtered, 
and the residue reextracted in water. Following 
centrifugation, dialysis and lyophilization, the 
samples were used (3,4). 




Group I. Blood Pressure 
Conscious rabbits were placed in canvas bags 
which were tied at the neck and blood pressure 
(BP) measured, via a heparinized 22 gauge needle 
and PE50 cannula inserted into the median ear 
artery, using a calibrated Hewlett-Packard 
transducer and recorder. Cetacaine spray was 
used as a topical anesthetic for needle in-
sertion. The cannula remained inserted through-
out the experiment and was flushed every 30 min 
with 1 ml of a 50% heparin-50% saline mixture. 
IOP and mean arterial BP were measured hourly 
over the course of 6 hours following initial 
pre-treatment measurements. IOP was measured 
using an Alcon Pneumatonograph. Values of TOP 
and BP for both experimental (received MDM in 
saline) and control (received equivalent volume 
of saline) groups were compared for each time 
interval within groups. 
Group II. Blood Gases  
Arterial blood samples were taken from a 
cannula in the median ear artery. Frequently in 
this series of experiments, BP was also measured 
hourly as described above. Blood (500-600 pl) 
was collected in pre-heparin rinsed 1 ml tuber-
culin syringes which were capped and stored in 
an ice bath until duplicate analyses were made 
using a Radiometer acid-base analyzer and a 
blood micro system. Analyses were usually made 
within 10 minutes of sampling. A control sample 
was taken before any treatment, either MDM in 
saline or saline alone, was administered. A 
small volume of blood was expelled from the 
syringe before placement of the sample in the 
blood-gas analyzer. Values of pH, PCO 2 , and PO 2 
 were determined for each sample. The pH was 
calibrated against precision buffer solutions 
and PCO
2 
calibrated using humidified gas 
mixtures with accurately known CO 2 concentra-
tions. Measurements were made at 37 ° C. In 
several experiments, body temperature was also 
measured using a calibrated YSI tele-thermometer 
and a rectal probe. A small amount of 5% lido-
caine ointment was administered prior to the 
probe insertion. The probe remained in place  
for 30 sec before the temperature was measured. 
Either a 1 mg or a 50 pg dose of MDM was admin-
istered. 
Group III. Repetitive Injection Experiments 
A group of rabbits was injected intravenously 
on day 1 with MDM in saline and the IOP recorded 
hourly for 6 hours after establishment of a 
time-zero baseline using -30 and 0 min readings 
which were averaged. The same rabbits received 
identical injections and determinations of IOP 
at weekly interva] . s over the next 5 weeks. 
Group IV. Incubation Experiments  
Experiments were performed in order to 
determine whether MDM activity was retained 
after incubation with saline, bovine serum al-
bumin solutions, whole blood, serum, aqueous 
humor or vitreous humor. The MDM concentration 
was adjusted to provide a dose of 50 pg/rabbit 
irrespective of the solution. 	In some cases, 
incubation of MDM with the solution was per-
formed at various times and temperatures. 
Group V. Reinjection Experiments  
This series was performed in two parts: a) 
systemic reinjection of blood, or serum and, b) 
intravitreal reinjection of aqueous or vitreous. 
a) Rabbits were given MDM systemically and, 
at various times, whole blood was removed via a 
cannulated carotid artery in an animal anesthet-
ized with xylazine and ketamine. 	Blood for 
whole blood reinjection was collected in a 
heparinized container, and blood for serum re-
injection was collected in non-heparinized 
tubes, allowed to clot and subsequently centri-
fuged. 	Either blood or serum from the MDM 
donors was then reinjected into other groups of 
rabbits and their TOP monitored over several 
hours. Because of the dilution of MDM in the 
donor rabbits, high doses were administered 
which, after appropriate dilution in the body 
water, would provide concentrations in the re-
injected whole blood or serum of approximately 
50 pg/animal. The latter concentration has been 
repeatedly shown to induce a large fall in TOP 
upon initial intravenous injection (1-3). 






Effects of 1 mg MDM fractions on rabbit blood pressure and intraocular pressure 
Times 
	
MDM # 1 
	
MDM #2 

















75.0 t 2.1 
77.7 t 2.6 
	
86.8 t 6.1 
68.3 ± 3.2 	-1.0 t 4.8 
64.7 t 4.7 +23.6 ± 8.8* 	73.1 t 8.1 
	
+24.1 t 5.4* 
C 	68.0 t 2.1 	-8.4 ± 3.8 
• 59.0 t 6.8 -10.3 ± 6.0 	55.1 ± 9.7 	-0.3 ± 6.5 
C 
	
70.2 ± 0.8 	-6.9 ± 4.0 
56.2 ± 5.0* -22.3 ± 10.2* 	52.9 ± 9.2 (11) 	-37.3 t 7.1* 
• 69.3 ± 2.3 
	
-2.0 ± 5.2 
59.6 ± 4.3 (5) 	-39.4 ± 9.8* 	64.7 t 5.3 (11) 	-48.8 ± 3.0* 
71.5 t 2.7 	-1.0 ± 4.2 
62.2 ± 4.2 (5) 	-59.2 ± 8.9* 	66.4 ± 6.3 (10) 	-53.3 t 4.2* 
68.9 t 2.7 	-0.2 ± 5.7 
• 58.5 ± 4.6 (4) 	-70.3 ± 4.8* 	66.1 ± 8.2 (7) 	-55.5 ± 5.9* 
C = control animals; E = experimental animals. MDM given intravenously at 1 mg per 
animal in 1 ml heparinized saline; controls received 1 ml heparinized saline. BP in 
mmHg is the average arterial pressure. Percent change in IOP calculated from the 
time-zero value (average of -30 min and 0 min readings). Values are the mean ± SEM; * 
P < 0.05 compared to the paired animal for MDM #1 and to pre-treatment values for MDM 
# 2. Number of animals = 6 for MDM #1, and 12 for MDM #2, unless indicated otherwise 
in parenthesis. 
intravitreally (2) with high concentrations (1 
ug) of MDM in 10 pl saline before subsequent 
removal of aqueous or vitreous and its 
reinjection intravitreally into other animals. 
The IOP was measured in the initial MDM donors 
in order to determine when the fall in IOP 
occurred for aqueous and vitreous retrieval 
purposes and, in the reinjected animals, to 
determine whether or not the MDM, or a metabo-
lite, remained active. The placement of 1 pg 
into 2 ml of vitreous gives a final 
concentration of 0.5 pg/ml. Reinjection of 50 
ul of this sample provides a dose of 25 ng 
which has repeatedly been shown to induce large 
unilateral IOP reductions in rabbit (2). 
Other experiments were performed in which 
aqueous or vitreous was removed from fresh eyes 
and MDM was incubated: with these fluids for  
either 6 or 24 hours at 37 ° C prior to injection 
unilaterally into rabbit eyes (the contralteral 
eyes received an equal volume of saline). The 
injected dose was 1 pg MDM in 10 ul of aqueous 
or vitreous. 
RESULTS 
Group I. Blood Pressure  
The data are shown in Table 1 for two 
derivatives, where it can be seen that although 
the BP tends to fall in both control and experi-
mental animals for MDM #1, there is no statisti-
cally significant difference between the saline-
and MDM-treated groups. When the response of 
each animal is examined, there is no correlation 
between those animals with large falls in BP and 
those animals with the greatest falls in IOP. 











pH T( ° C) 
0 C 32.5 t 2.0 77.3 ± 	2.5 7.47 ± 0.03 39.3 ± 0.2 
E 35.5 t 2.2 73.3 ± 	5.0 7.46 t 0.02 38.9 ± 0.5 
C 31.0 	± 	1.5 77.0 	± 	2.5 7.46 ± 0.02 39.7 ± 0.2 
E 25.6 ± 1.8* 68.1 ± 12.8 7.45 t 0.01 40.8 ± 0.4 
2 C 29.9 ± 	1.0 79.9 ± 	2.5 7.44 t 0.02 39.5 ± 0.3 
E 19.3 	± 1.6* 79.6 ± 	7.1 7.40 t 0.06 39.6 ± 0.5 
3 C 27.0 t 	1.3 81.4 t 	3.7 7.45 ± 0.02 39.5 ± 0.3 
E 16.7 t 1.5* 90.5 ± 	5.4 7.37 ± 0.02* 39.6 ± 0.6 
4 C 27.9 	± 	1.0 80.0 ± 	1.5 7.45 ± 0.02 39.8 ± 	0.3 
E 17.5 ± 	2.1*(5) 84.9 	± 	1.7 	(5) 7.40 ± 0.01 	(5) 40.3 ± 0.4 
5 C 26.6 ± 0.9 81.1 ± 	1.5 7.44 ± 0.02 40.1 ± 0.4 
E 17.9 ± 1.8*(4) 88.5 ± 	1.9*(4) 7.40 ± 0.03 	(4) 40.5 ± 0.4 (5) 
6 C 26.0 ± 0.8 80.6 ± 	1.2 7.45 ± 0.01 40.2 ± 0.3 
E 19.3 ± 2.7*(4) 87.8 ± 	0.8*(4) 7.37 ± 0.03*(4) 40.1 ± 0.6 (4) 
C = control, received 1 ml heparinized saline; E = experimental, received 1 mg MDM in 
1 ml heparinized saline. PCO 2 and PO givengiven in mmHg. Values are the mean ± SEM of 6 
animals, unless indicated otherwise in parenthesis. * P < 0.05 comparing control and 
experimental rabbits. 
spite wide variations in IOP caused by 1 mg of 
MDM #1, from an increase of 24% at 1 hour, to a 
statistically significant fall of 60% or 70% at 
5 to 6 hours. With 1 mg of MDM #2, no parallel 
control series were performed; but, neverthe-
less, there is no statistically significant 
change in BP compared to pre-drug values despite 
a statistically significant rise in IOP at 1 
hour and a fall after 3 to 6 hours. 
Group II. Blood Gases  
With an MDM dose of 1 mg/rabbit, body 
temperature and P0
2 
remained constant or in-
creased (P0
2
) during the course of the 6 hour 
experiment. PCO 2 , on the other hand, although 
decreasing even in control animals relative to 
pre-test values, decreased to values between 75% 
and 80% of the controls in 1 mg MDM-treated 
animals (Table 2). Concurrent with the fall in 
PCO 2, there is a statistically significant fall 
in pH of MDM-treated animals at 3 and 6 hours. 
The IOP (see Table 1), however, showed an in- 
crease at 1 hour which was followed by a pro-
longed and marked fall from 3 to 6 hours. 
Systemic injection of 50 pg, which is a dose 
level known to cause a substantial fall in IOP 
of over 40% (1,2, also Table 3), caused no 
changes in BP or blood pH, P0 2 or PCO2 . Thus, 
MDM was without effect on parameters which could 
explain, at least in part, the fall in IOP at 
this dose level. 
Group III. Repeated Injections  
Injection of MDM in successive weeks, at a 
dose level sufficient to induce a marked fall in 
IOP on day 1 of week 1, caused a lessened fall 
of IOP on successive weeks (Table 4). By weeks 
4 and 5, the response to MDM is almost elimi-
nated, and the results resemble those obtained 
from a saline injection only (compare Table 1). 
Another series of 8 animals received 25 pg of 
MDM intravenously on day 1 and showed a maximum 
fall in IOP of 33.2 t 6.0% at 6 hours. Injec-













0 C 33.4 t 	1.2 70.2 ± 4.5 7.44 t 0.01 28.0 ± 	1.1 83.2 ± 	1.6 
E 30.6 t 	1.7 75.9 ± 	4.2 7.46 ± 0.02 29.7 ± 	1.1 81.8 ± 	2.5 
1 C 28.0 ± 1.1 74.6 ± 	3.6 7.44 ± 0.01 -2.0 ± 	5.1 76.0 ± 2.3 
E 26.5 t 	1.3 75.9 ± 	2.1 7.44 ± 0.01 7.2 ± 	4.8 72.5 ± 	1.9 
2 C 29.2 ± 0.9 70.5 ± 	2.6 7.43 ± 0.01 -2.8 ± 	5.6 75.7 ± 1.8 
E 22.5 ± 	2.1* 79.0 ± 	3.1 7.43 ± 0.01 2.8 ± 10.4 76.8 ± 	3.8 
3 C 25.1 ± 0.9 73.8 ± 	2.8 7.44 ± 0.01 -1.4 ± 	4.3 78.8 ± 1.4 
E 23.7 ± 	1.8 74.4 ± 	3.4 7.43 ± 0.01 -13.8 ± 10.5 77.7 t 3.7 
4 C 25.7 ± 	0.8 72.4 ± 	1.0 7.44 ± 0.01 2.1 t 	5.2 78.8 ± 1.4 
E 23.9 ± 1.1 79.1 ± 	3.1 7.43 ± 0.01 -36.7 ± 	6.9* 76.5 ± 	2.5 
5 C 25.4 ± 0.9 76.0 ± 3.0 7.45 ± 0.01 -5.8 ± 	5.4 76.7 ± 	3.3 
E 25.1 ± 0.8 77.7 ± 	3.5 7.43 ± 0.01 -44.9 ± 	5.4* 72.5 t 	1.6 
6 C 25.1 ± 1.0 (5) 77.1 ± 	3.2 7.44 ± 0.01 - 2.0 ± 	3.5 78.8 ± 	2.2 
E 25.4 ± 	1.0 (5) 76.5 ± 	2.4 (5) 7.42 ± 0.01 (5) -48.6 ± 	3.9*(5) 67.0 t 	3.7* (5) 
C = Control, received 1 ml heparinized saline; E = experimental, received 50 pg MDM in 1 ml 
heparinized saline. PC0 9 , P0 2 and BP given in mmHg. 0 hour TOP in mmHg; all succeeding 
values are % change. Vanes are the mean t SEM of 6 animals, unless indicated otherwise in 
parentheses. * P < 0.05 comparing control and experimental rabbits. 
in a maximum fall in IOP of 27.6 ± 4.7% at 5 
hours. Thus, the time course and overall magni-
tude of the response was similar on both days. 
Whether this is a consequence of a lower dose 
administered on day 2 remains unknown. MDM, at 
25 pg, in fresh rabbits caused a maximal IOP 
fall of 30.0 ± 3.8% at 4 hours. Thus, the in-
duced fall in IOP is similar to that caused in 
the repetitive injection series after the first 
injection. 
Group IV. Incubation Experiments  
MDM incubated in saline for 1 hour at 37 ° C, 
when injected intravenously into rabbits (50 
ug/animal), induced a fall in TOP of 23.0 ± 3.5% 
(n=8) at 5 hours (see also Table 1). MDM was 
then incubated with fresh whole blood or serum 
for 1 hour at 37 ° C or for 20 hours at room tem-
perature before intravenous injection into rab-
bits. The MDM dose was 25 pg or 50 pg/animal 
but no IOP fall was noted from either whole 
blood or serum in the presence or absence of 
MDM. When incubated for 1 hour at 37 ° C, MDM in 
either 100 mg% or 1000 mg% bovine serum albumin 
(BSA) induced maximal falls in IOP of 49.4 ± 
3.9% (n=8) and 39.6 ± 3.2% (n=8), respectively, 
when given at 50 pg MDM/animal in 1 ml of BSA 
solution. Intravenous injection of 1 ml of 1000 
mg% BSA solution alone induced a maximal fall in 
IOP of 14.2 t 3.7% (n=8). When MDM was in-
cubated for 1 hour at 37 ° C with either fresh 
aqueous or vitreous, the IOP fell by 24.5 t 5.5% 
and 35.7 t 4.0%, respectively, upon intravenous 
injection of these solutions at 50 ug MDM/animal 
indicating that MDM was unaffected by exposure 
to aqueous or vitreous. 
The data with incubation of MDM with whole 
serum (vide supra) raised the possibility that 










2 	 3 
	
4 	 5 
	
6 	 7 
Week 1 
% Change in IOP 
Week 2 
X Change in IOP 
Week 3 (n = 7) 
% Change in IOP 
Week 4 (n = 5) 
% Change in IOP 
Week 5 (n = 5) 
Change in IOP 
+9.5 ± 4.1 	+0.3 ± 4.8 	-11.3 ± 5.0 
-8.1 ± 2.7 	-4.9 ± 4.0 	-9.1 ± 3.0 
-1.5 ± 1.5 	-2.5 ± 4.9 	-5.5 ± 4.0 
-2.1 ± 4.6 	-6.2 ± 3.8 	-9.3 ± 6.2 
-5.8 ± 1.3 	-15.1 ± 4.1 	-7.7 ± 2.8 
-31.6 ± 3.8* 
-9.9 ± 1.7 
-13.5 ± 3.3 
-10.7 ± 3.0 
-6.1 ± 3.3 
-32.8 ± 3.7* 
-17.4 ± 1.9* 
-19.2 ± 4.0* 
-0.5 ± 6.0 
-8.9 ± 3.7 
-34.2 ± 3.9* 
-20.8 ± 2.6* 
-17.4 ± 3.9* 
-7.1 ± 4.2 
-6.2 ± 2.4 
-35.8 ± 3.8* 
-18.6 ± 2.5* 
-15.7 ± 4.7* 
-7.1 ± 3.3 
-9.1 ± 2.3 
Repeated injection of 50 gg MDM were given weekly. Percent fall in IOP calculated from time zero value of IOP (average 
of -30 min and 0 min readings prior to injections). Values are the mean ± SEM. n = 8 unless otherwise indicated in 
parenthesis. * P < 0.05 compared to control, pre-treatment values. 
MDM binding or chemical modification. To study 
this in greater detail, 10 ml of serum was 
dialyzed against 1000 ml distilled water at room 
temperature for 24 hours. Both the retentate 
and dialysate were freeze-dried, and reconsti-
tuted in 10 ml of heparinized saline containing 
500 pg MDM and incubated at 37 ° C for 1 hour. 
Eight rabbits were injected with either recon-
stituted dialysate or retentate containing 
sufficient MDM to give 50 pg/animal. Both solu-
tions caused a marked fall in TOP; serum reten-
tate, 29.6 ± 3.4% at 6 hours and serum dialy-
sate, 37.7 ± 2.3% at 6 hours. 
Group V. Reinjection Experiments  
a) Systemic Readministration. MDM was given 
to rabbits at a systemic dose of 2 mg. Given 
distribution in only the vascular system of the 
donor rabbits (due to the large molecular size 
and the short time after injection), this should 
result in 1 ml of blood containing about 10 pg, 
thus reinjection of 2.5 ml should result in ap-
proximately 20 to 25 pg of MDM being adminis-
tered to the recipient animals. Experiments 
performed with whole blood and plasma retrieval 
at 7 minutes after the initial 2 mg MDM injec-
tion resulted in a fall in TOP in recipient  
rabbits which was a maximum of 36.8 ± 3.8% at 6 
hours after reinjection. At 2 hours after 2 mg 
MDM, retrieval of whole blood or serum and 
subsequent reinjection into other animals failed 
to induce any change in IOP over 7 hours (2 
series, maximum fall in IOP, 8.9 ± 3.1% at 1 
hour [n=8] and 7.2 ± 3.3% [n=8] at 5 hours). 
Similar results (maximal fall in TOP, 9.4 ± 2.6% 
[n=8] at 3 hours) were obtained when blood was 
taken at 6 hours (the time of maximal TOP fall 
in the initially-injected donor rabbits). At 24 
hours after the initial injection, reinjection 
of 2.5 ml of serum from donor animals into fresh 
rabbits caused a maximal fall in TOP of 24.1 t 
2.4% at 4 hours after injection. Recovery of 
whole blood and serum from rabbits at 8 minutes 
after receiving 10 mg MDM caused a maximal TOP 
fall of 54.8 ± 4.0% at 6 hours after reinjection 
into recipient rabbits. 
	
b) Intraocular Readministration. 	Incubation 
of MDM for 6 hours with fresh aqueous or vi-
treous, when injected into vitreous of fresh 
rabbits at a dose of 1 pg MDM/10 pl aqueous or 
vitreous, initiated a large unilateral fall in 
TOP in the MDM-injected eye (Table 5). Incuba-






Effects of 1 pg MDM when incubated with aqueous or vitreous 
Eye Injection Time % Fall in IOP 
OS (n = 4) Saline 24 hr. 5.5 ± 	14.1 
42 hr. 13.9 ± 	11.5 
95 hr. 15.6 ± 	14.6 
OD (n = 4) MDM incubated in 24 hr. 22.6 ± 	4.1* 
aqueous for 6 hr 42 hr. 49.6 t 	3.3* 
95 hr. 44.8 ± 	4.5* 
OS (n = 4) Saline 24 hr. 14.2 ± 	9.8 
42 hr. 16.9 ± 	6.1 
95 hr. 12.4 ± 	2.7 
OD (n = 4) MDM incubated in 24 hr. 38.4 ± 	3.6* 
vitreous for 6 hr 42 hr. 39.6 ± 	2.3* 
95 hr. 40.0 ± 	4.3* 
MDM was incubated with fresh aqueous or vitreous for 6 hours and injected 
intravitreally in 10 pl aqueous or vitreous into rabbits. Percent fall in 
TOP was calculated from time-zero values; values are the mean ± SEM. * P < 
0.05 compared to paired, saline-treated eye. 
comparing saline-injected and MDM-injected eyes 
(Table 6). The 6 hour incubation indicated that 
neither aqueous nor vitreous alone influenced 
the effect of intravitreal MDM. Intravitreal 
MDM at 1 ug/eye induced a large fall in IOP in 
the recipient eye, while the contralateral 
saline-treated eye showed only a minimal fall in 
IOP (2). 
A further experiment was performed in which 1 
pg of MDM in 10 pl saline or 10 pl saline alone 
was injected intravitreally into paired eyes of 
recipient rabbits. At 26 hours after these in-
jections, when the donor rabbit IOP was at a 
minimum, both aqueous and vitreous were col-
lected from these MDM-in j ected eyes and 50 pl of 
the collected aqueous or vitreous reinjected in-
travitreally and unilaterally into fresh eyes 
(saline was injected into the contralateral 
eyes). Given an ocular volume of 2 ml, the in-
jection of 1 pg would give 0.5 pg/ml or 0.025 
ug/50 pl; reinjection of 0.025 pg per eye should 
induce a marked unilateral fall in IOP (2). The 
data in Table 7 indicate that reinjection of  
aqueous and vitreous that had received saline 
alone caused a substantial fall in IOP which 
tended to recover to near normal values after 49 
hours. With aqueous from eyes previously in-
jected with MDM, however, the TOP stayed low for 
a considerably longer period of time. Little 
difference was seen between the vitreous rein-
jection using either saline or MDM-treated 
vitreous. 
DISCUSSION 
Several water-soluble fractions of material 
isolated from marihuana have proven effective in 
reducing IOP in rabbit and dog when given sys-
temically (1-3) and in the primate and rabbit 
when given intravitreally (2). Recent studies 
on purer fractions have indicated that the pro-
tein content is relatively small and that the 
carbohydrate fraction is correspondingly large 
(3,4). Chemical analyses have delineated the 
composition of these fractions with considerable 
accuracy (3). Three active and potent fractions 
of high (5 x 10
5 






Effects of 1 Vg  MDM when incubated with aqueous or vitreous 
Eye Injection Time % Fall in IOP 
OS 	(n = 4) Saline 24 hr. 25.7 	t 	7.5 
48 hr. 31.1 	t 	5.8 
142 hr. 13.9 	t 	5.5 
OD (n = 4) MDM incubated in 24 hr. 30.1 t 	4.9 
aqueous for 24 hr 48 hr. 37.6 t 	1.8 
142 hr. 18.7 	t 	5.8 
OS (n = 4) Saline 24 hr. 21.6 	t 	7.2 
48 hr. 32.8 t 	6.7 
142 hr. 15.8 ± 	8.8 
OD (n = 4) MDM incubated in 24 hr. 38.9 	t 	6.0 
vitreous for 24 hr 48 hr. 50.3 	± 	2.7* 
142 hr. 21.1 	± 	14.2 
MDM was incubated with fresh aqueous or vitreous for 24 hours and injected 
intravitreally in 10u1 aqueous or vitreous into rabbits. Percent fall in 
IOP calculated from time-zero values; values are the mean t SEM. * P < 
0.05 compared to paired, saline-treated eye. 
Table 7. 
Effect of injection of aqueous or vitreous 
from previously injected rabbits 
Eye 	 Injection 	 Time 	 % Fall in IOP 
OD 	 Aqueous from eye 	 26 hr 	 30.1 t 8.0 
(n = 4) 	 previously injected 	42 hr 23.6 t 4.9 
with sterile saline 49 hr 	 4.2 t 7.6 
OS 	 Aqueous from eye 	 26 hr 	 7.7 ± 2.4 
(n = 4) 	 previously injected 	42 hr 26.8 t 11.4 
with 1 ug MDM 	 49 hr 	 26.7 t 13.4* 
OD 	 Vitreous from eye 	 26 hr 	 16.3 t 2.8 
(n = 4) 	 previously injected 42 hr 18.2 ± 4.5 
with sterile saline 	49 hr 	 5.2 ± 5.6 
OS 	 Vitreous from eye 	 26 hr 	 10.0 t 8.0 
(n = 4) 	 previously injected 42 hr 19.4 t 3.8 
with 1 jig MDM 	 49 hr 	 0.9 ± 6.6 
Percent fall in IOP calculated from time-zero values; values are the mean ± 
SEM. * P < 0.05 compared to paired eye. 
been identified (4). MDM #1 and #2 are two of 
these fractions. 
Earlier studies of MDM effects in rabbits  
indicated that BP was unaffected when compared 
to saline-treated animals, but measurements were 





and with cannula reinsertion at appropriate 
times. Despite the use of a topical anesthetic, 
the manipulative procedures could evoke dis-
turbance of the normal pattern of BP; thus, the 
present studies were designed to overcome these 
difficulties. A continually implanted cannula 
served as the means by which BP was monitored 
frequently. Despite the injection of a high 
concentration of MDM (1 mg compared to 50 ug; 
the latter is the dose which normally reduces 
IOP by at least 40%), there is no statistically 
significant effect on BP (Table 2). Such a high 
concentration of MDM was used in order to 
accentuate any systemic effects which might be 
induced. With a dose of 50 pg MDM, it was 
verified that no change in BP occurred (Table 
3), despite an over 40% fall in IOP. The IOP 
during the first 6 hours after injection of a 
high concentration (1 mg) of MDM undergoes a 
marked rise by as much as 25% within 1 hour, 
followed quickly by a fall to about 60% of the 
baseline IOP within 3 tc 5 hours (Table 1). No 
correlation exists, therefore, between BP and 
IOP during the course of the IOP change and the 
IOP fluctuations must be caused by effects other 
than BP. Dose levels of 1 mg and greater per 
animal have been previously shown to cause re-
laxation of conscious rabbits sufficient that 
muscle tone is lost and the animal becomes 
flaccid (1). 
Body temperature and P0 2 remain constant 
during the first 6 hours after administration of 
1 mg MDM. PCO2 and pH, however, show a de-
crease, particularly of PCO 2 . Although no 
changes in blood gases occurred which might 
correlate with the increase in IOP at 1 hour, 
there does appear to be some relationship be-
tween PCO
2 
and the fall in IOP. Acidosis (5) 
and reduction in PCO2 (6) have been shown to 
reduce IOP by effects on aqueous inflow (5). 
Previous studies have linked the fall in IOP 
with a change in either pH (5,6) or PCO 2 (7). 
Our studies indicate non-significant changes in 
blood pH (except at 3 and 6 hours) but signifi-
cant falls in PCO
2 
from the second hour after 
MDM-administration. 	The present data, there- 
fore, indicate that PCO
2 
changes alone can 
account for some of the the fall in IOP. 
Induced metabolic acidosis reduced the IOP for 
at least an hour (5) but no comment was made on 
the duration of the fall in IOP, although the 
maximal fall was reached at 30 min and rose 
gradually during the next 30 min but not 
regaining the original value. Aqueous inflow 
was decreased by over 50% (5) with large 
systemic changes in pH, which correlates with 
our findings of an 80% fall in aqueous inflow 
with MDM. It is possible, therefore, that at 
least part of the explanation for the effects of 
large doses of MDM lies in the induction of a 
loss of CO2 , and a degree of acidosis. Intra-
venous HC1 is known to reduce the IOP by approx-
imately 30% and pH by 0.16 units after 30 min, 
while the reduced aqueous inflow was measured at 
1 hour (5). MDM is known to reduce IOP by at 
least 50 to 55% by 6 hcurs after administration 
at the dose levels (1 mg) employed here (Table 
1), thus acidosis caused by the fall in PCO 2 
 could be responsible for approximately 25% of 
the total IOP fall caused by MDM at this dose 
level. This value is obtained from a considera-
tion of the fall in IOP for a given change in 
PCO 2, based upon earlier studies (5,6). The 
maximum pH difference between control and MDM-
treated animals was a non-significant 0.08 
units, while the maximal PCO2 difference was 
10.4 mmHg. The rate of change of PCO 2 has been 
linked to the change in IOP, as well as the 
retention of low IOP in the face of normal 
values for PCO 2 and pH after a decrease in the 
latter parameters (7). The rate of change in 
the present experiments (Table 2) was relatively 
slow, although the amount of change (approxi-
mately 10 to 12 mmHg) in these other series 
(7,8) did cause a fall in IOP of about 35%. 
A low dose level of MDM, 50 pg, which still 
induced a large (50%) fall in IOP (Table 3) 
caused no change in BP, pH or PCO 2 . Thus, no 
relationship exists at lower MDM doses which 





systemic blood 	gas 	chemistry, 	and 	other 
explanations must be sought to explain the fall 
in 10P. 
Repeated injections of MDM into the same 
animals resulted in a decreasing effect with 
time, indicating a tachyphylaxis to MDM. The 
reasons for this effect remain undetermined, but 
the data confirm earlier findings after daily 
administration (1). It is surprising that even 
at weekly intervals that there is a tachyphy-
laxis since the IOP, after a single administra-
tion, returns to normal levels by between 28 and 
36 hours at the dose levels employed in this 
series (50 ug/animal). 
The incubation and reinjection experiments 
indicate several important facts concerning the 
behavior of MDM. First, the incubation at 37 ° C 
in saline in the presence or absence of BSA has 
no effect on its subsequent effect in the rab-
bit, although incubation with serum or whole 
blood inactivates the material. Secondly, 
incubation of MDM for 1 hour at 37 ° C with 
aqueous or vitreous with subsequent intravenous 
injection again has no effect on the MDM-induced 
response, indicating that neither aqueous or 
vitreous contain the mechanism for deactivation 
of MDM. It is unlikely that the lack of effect 
after incubation in whole blood or serum re-
flects binding since an unaltered response was 
elicited by MDM in a 1000 mg percent BSA solu-
tion. The absence of a response when MDM was 
incubated in whole blood or serum appears to 
reflect a change induced by some breakdown or 
modification of MDM. This must remain to be 
determined, however, since intravenous admini-
stration of MDM still causes alterations in IOP 
either in short-term (elevation at 1 hour) or 
long-term (decrease by 3-4 hours) in vivo. 
Thus, the in vivo data indicate that whatever 
effect blood or plasma has on MDM does not 
affect its pharmacological properties, whereas 
in vitro incubation with whole blood or plasma 
appear to render MDM pharmacologically inactive 
when injected into fresh rabbits. If metabolism 
occurs in vivo, an explanation must be sought  
for the inability of whole blood to perform this 
event in vitro with subsequent in vivo effects 
upon injection. 
The results from reinjection of whole blood or 
serum from initial donor animals indicate that 
only at short time intervals after high doses of 
MDM injection are effects seen in recipient rab-
bits. High 2 mg) dose levels presumably 
either have little opportunity to distribute in 
the available body water, are not bound or 
metabolized by whole blood or present such an 
excess of material to the donor system that 
binding/metabolizing loci cannot handle the 
load. Whatever the reason, there is also little 
question that at times when the donor rabbit 10P 
is either elevated (due to the high dose level) 
or depressed, there is no effect seen in rabbits 
which are recipients of donor whole blood or 
serum. There was a suggestion that recovery of 
blood at 24 hours did cause an effect when rein-
jected into fresh recipient rabbits. 
Reinjection of aqueous from a previously 
MDM-injected eye into fresh recipient eyes did 
cause a reduction in IOP which was greater than 
that caused by aqueous from a contralateral 
saline-injected eye. There was no difference 
between vitreous recovered from either MDM or 
saline-injected eyes. It is possible that the 
MDM had either become bound to ocular tissues or 
passed from the vitreous into the aqueous since 
the latter pathway would be that which a 
material of this size would follow. The aqueous 
reinjection data indicate that MDM does indeed 
pass through the aqueous on its way out of the 
eye and that it remains active. Perhaps this is 
a consequence of the small amount of material 
necessary to induce a response when MDM is 
placed intravitreally. MDM which is neither 
metabolized, bound or consumed during passage 
from vitreous to aqueous is that which is 
retrieved and remains active upon reinjection. 
Perhaps the reason for the lack of vitreous 
effect is due to the loss of MDM in the time 
interval chosen for this experiment. 





is somehow removed from the vascular circulation 
within a very short time after intravenous in-
jection because subsequent removal of whole 
blood or serum and reinjection into other ani-
mals does not reduce IOP in the recipients; that 
incubation in media other than whole blood or 
serum does not decrease activity, whereas in-
cubation in whole blood or serum inactivates the 
material; and that, although high (1 mg) doses 
of MDM cause systemic acidosis, low dose levels 
(50 ug/rabbit) do not induce changes in blood 
gas chemistry indicating that this mechanism 
does not account for the fall in IOP. 
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SUMMARY 
Aqueous extraction of air dried Cannabis sativa (marijuana) yields, after 
dialysis, a mixture of high molecular weight carbohydrate-containing 
components. This mixture has very potent intraocular pressure-lowering 
activity (antiglaucorna) when tested by intravenous injection into rabbits. 
Partial purification by DEAE-cellulose and gel filtration chromatography 
has yielded very active material (lowers intraocular pressure maximally at 
1 pglanimal) with an estimated molecular weight of about 500 000. The 
active material contains mostly carbohydrate with a small amount of 
protein. Rhamnose, galactose and uronic acid are the major sugar con-
stituents. The composition of components suggests that the active material 
is a pectic polysaccharide possibly derived from the cell wall. 
INTRODUCTION 
We have discovered a novel activity for polysaccharides solubilized from 
dried leaves of Cannabis sativa by extraction with hot water. These 
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carbohydrates, which have certain chemical and physical characteristics 
of pectic polysaccharides, lower intraocular pressure (IOP) when injected 
intravenously into rabbits. We have shown that these water-soluble 
materials lower IOP by a different mechanism (Green et al., 1981, 1982) 
from certain cannabinoids (Green, 1982). Since the elevated IOP caused 
by glaucoma is a major cause of blindness, this polysaccharide material 
may have pharmaceutical applications. Further chemical investigations 
of these carbohydrates were therefore undertaken, and the results are 
reported in this paper. 
EXPERIMENTAL 
Extraction of Cannabis sativa 
Samples of dried marijuana (primarily leaves and small stems of 
Czechoslovakian variety) were obtained from the University of Missis-
sippi Research Institute for Pharmaceutical Sciences under the auspices 
of the National Institute of Drug Abuse. Portions were macerated in a 
Waring blender (3.8 litre capacity) with warm (55-60 °C) water (eight 
times the weight of the sample). Optimum activity was obtained from 
samples blended at low speed (15 500 rpm) for 0.5-1.0 min. The 
macerated samples were filtered through cheesecloth under vacuum, 
and the residue was then re-extracted with warm water without further 
maceration. Extracts were centrifuged at 1340 g for 60 min; the super-
natants were dialyzed against distilled water, lyophilized and tested for 
IOP-lowering activity. 
Ion exchange chromatography 
Crude, dialyzed extracts were lyophilized and then applied to a column 
(2.5 cm X 45 cm) of DEAE-cellulose equilibrated in 0.05 M Tris-HC1, 
0.25 M NaCl, pH 6.7. The first 250 nil eluting under these conditions 
were pooled, dialyzed against water and lyophilized. Highly-coloured 
material was retained on the column. 
Chemical analysis 
The carbohydrate compositions of various samples were determined by 
gas chromatography of the alditol acetates using the method of Albers-
heim et al. (1967). Gas chromatography using flame ionization detec-
tion (FID) was performed with a 2 mm X 1.8 in column of SP 2340 and 
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a temperature programme beginning at 190 °C for 5 min and then 5 °C 
per min to 275 °C. Helium was used as the carrier gas at a flow rate of 
30 ml/min. 
Total neutral sugar was determined by the phenol-sulphuric acid 
method of DuBois et al. (1956), using n-glucose as standard. 
Partial amino acid analyses were performed on acid hydrolysates 
(6 M HC1, 18 h, 110 °C in vacuo) by ion-exchange chromatography using 
post-column derivatization with ninhydrin. 
Uronic acid content was determined by the method of Blumenkrantz 
& Asboe-Hansen (1973), using o-phenylphenol (Sigma) as reagent and 
galacturonic acid as the standard. 
Protein content was determined by the Lowry method (Lowry et al., 
1951) using bovine serum albumin as the standard. 
Reduction of uronic acids 
Uronic acids were reduced with NaBH 4 after activation of carboxyl 
groups with a water-soluble carbodiimide, 1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide (Sigma), according to the method of Taylor et al. 
(1976), scaled to a 1 mg sample. The reduced polysaccharide, recovered 
by lyophilization instead of precipitation, was hydrolyzed, and the 
products were converted to alditol acetates for analysis as described 
above. 
Gel filtration chromatography 
A column (1.5 cm X 45 cm) of Fractogel TSK HW-65F (Merck) was 
equilibrated in 0.05 M (NH 4)2CO 3, pH 7.8. Samples (100 mg) of DEAE-
cellulose fractions were applied, and 1.4-ml fractions were collected. 
Aliquots of fractions were assayed for total carbohydrate, uronic acid, 
protein, neutral sugar, and IOP-lowering activity. 
Chromatography on Fractogel TSK HW-65F was performed with 
three other solvent systems: 0.05 M sodium phosphate-0.2 M LiBr, pH 
6.5; 4 m guanidine hydrochloride; and 0.5 m NaCl containing 0.005 m 
EDTA. 
Affinity chromatography 
A column containing Concanavalin A-agarose (Sigma) was equilibrated 
in solvent containing 1 mm MnC1 2 , 1 mm MgC12, and 0.1 M NaCl. The pH 
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was adjusted to 5.3 with acetic acid. A sample of DEAE-cellulose 
fraction was applied in the same solvent, and the column was eluted 
with one column volume of equilibrating solvent. The column was then 
eluted successively with one column volume each of solvents containing 
20 mm a-methyl-D-mannoside and 200 mm a-methyl-D-mannoside. The 
three fractions were dialyzed against distilled water, lyophilized, and 
analyzed for carbohydrate and IOP-lowering activity. 
A column of Ricinus communis agarose (RCA-I, E-Y Laboratories) 
was equilibrated in 0.01 M Tris-HC1, 0.1 M NaC1, pH 7.65. A sample of 
active fraction 2 was applied in this buffer. The column was eluted 
with successive column volumes of starting buffer and buffers contain-
ing 20 mm and 200 mm 0-methyl-D-galactoside. Each of the three frac-
tions was dialyzed against distilled water, lyophilized, and analyzed for 
'OP-lowering activity. 
Chromatofocusing 
A column (1.0 cm X 30 cm) was packed with PBE 94 (Pharmacia) and 
equilibrated in 0.025 M imidazole-HC1 buffer, pH 7.35. Polybuffer 
(Pharmacia) (5 ml), pH 4.0, was passed through the column, and then 
a sample of a DEAE-cellulose fraction in imidazole buffer was applied. 
The column was eluted with Polybuffer, pH 4.0, and the effluent was 
monitored at 280 nm. Fractions were collected, and aliquots were 
assayed for neutral sugar. The pH of the fractions was also monitored. 
Washing the column with 1 M NaCl removed material bound at pH 4.0. 
Polyacrylamide gel electrophoresis 
Polyacrylamide gel electrophoresis was performed according to Gabriel 
(1971). 
Pronase digestion 
A 6.4 mg sample of a DEAE-cellulose fraction was dissolved in 1 ml of 
0.15 M Tris acetate-0.0015 M calcium acetate, pH 8.0. Digestion was 
carried out at 37 °C in the presence of toluene as an antibacterial agent 
for 72 h with five additions of pronase (Sigma Protease XIV). The total 
sample volume was then applied to the gel filtration column, and carbo-
hydrate was monitored by the phenol-sulphuric acid assay. 
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Alkaline borohydride reaction 
A 1.4 mg sample of an active fraction obtained from DEAE-cellulose 
chromatography was dissolved in 1.4 ml of 0.05 M NaOH containing 
1 NI NaBH4 and heated at 50 °C for 15 h. An aliquot was taken for IOP 
testing, and the remainder was applied to the gel filtration column. 
Fractions were monitored for carbohydrate by the phenol-sulphuric 
acid assay. 
Intraocular-pressure screening 
IOP measurements were made with an Alcon Pneumatonograph on 
both eyes of an adult rabbit. Baseline values were obtained on readings 
30 min prior to and just before the time of intravenous injection of the 
sample to be tested . . Seven hourly measurements were made after 
delivery of the sample. Measurements taken from four rabbits treated 
identically at the same time were averaged, and percentage changes in 
IOP are reported. Additional details of the assay have been described by 
Deutsch et al. (1981) and Green et al. (1981). 
RESULTS AND DISCUSSION 
All water extracts and subsequent fractions obtained from Cannabis 
sativa were tested for IOP-lowering activity by intravenous injection 
into rabbits (Green et al., 1981; Deutsch et al., 1981). In these assays, 
activity is expressed as the percentage fall in IOP after administering the 
sample compared with resting pressure. The maximum percentage fall is 
about 60%, at which point the IOP is equal to venous pressure. 
Water extracts from Cannabis sativa were dialyzed and fractionated 
on DEAE-cellulose. 13atchwise elution of DEAE-cellulose using 0.05 
Tris-HC1, pH 6.7, containing 0.25 M NaCl yielded an active material used 
for subsequent studies to characterize the active component. Attempted 
elution of extracts at lower ionic strength resulted in material becoming 
irreversibly bound to the resin. 
The active fraction from DEAE-cellulose chromatography was 
analyzed for carbohydrate and protein content. Carbohydrate analysis 
of the active DEAR-cellulose fraction showed the presence of about 
36% neutral sugar by weight (Table 1), and the relative proportions of 
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TABLE 1 
Composition of Fractions (Weight Per Cent) Obtained from Water Extract 
of Cannabis sativa 
Fraction Neutral sugar' Uronic acidb Proteinc 
DEAE-cellulose 36 12 26 
Fractogel 
1 19 3 38d 
2 22 12 16d 
3 22 10 23d 
a Determined by phenol-sulphuric acid assay. 
b Determined by o-phenylphenol assay. 
Determined by Lowry method. 
d Determined by amino acid analyses. 
TABLE 2 
Neutral Sugar Composition a (Mol Per Cent of Total Neutral Sugar) of 
DEAE-Cellulose Fraction Before and After Carbodiimide-Activated 
Reduction of Uronic Acids 
Sugar Without reduction of 
uronic acid 
With reduction of 
uronic acid 
Rhamnose 14.2 13.1 
Arabinose 31.1 22.5 
Xylose 6.6 7.6 
Mannose 3.8 5.1 
Galactose 35.4 41.8 
Glucose 11.0 9.9 
Glucosamine trace trace 
a Determined by g.c. analysis of alditol acetates. 
neutral sugars were determined by gas chromatography of the alditol 
acetates (Table 2). The protein content of each fraction, as determined 
by the Lowry colorimetric test, and the uronic acid content, as deter-
mined by the o-phenylphenol colorimetric test, are also listed in Table 1. 
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The type of uronic acids present in the active material was ascertained 
by reduction of the acids to the corresponding neutral sugars by the 
method of Taylor et al. (1976). A sample of the DEAE-cellulose frac-
tion was treated with a water-soluble carbodiimide and reduced with 
NaBH4. Reduction of uronic acids was 98% complete, based on the 
colorimetric response of a control sample before and after reduction 
using the o-phenylphenol reagent. Recovery of material was ascertained 
by phenol-sulphuric acid assay before and after reduction; according 
to this method, virtually 100% of the material was recovered. The 
reduced sample was then hydrolyzed and subsequently converted to the 
alditol acetates in the normal fashion. The neutral sugar composition 
showed significant changes in the amounts of only two of the sugars, 
arabinose and galactose (Table 2). The arabinose content decreased by 
almost 9%. In our hands, the method used for the reduction of uronic 
acids has resulted in loss of arabinose in all samples tested, including 
standards such as gum arabic. The acidic conditions of the reduction 
may cause this loss of arabinose. The galactose content showed a 6% 
increase compared with the non-treated control. These results suggest 
that the predominant uronic acid present in the active sample is galac-
turonic acid. The degree of esterification of the uronic acids has not yet 
been determined. 
An attempt was made to purify the DEAE-cellulose fraction further 
by means of the affinity of its carbohydrate moieties for Concanavalin 
A, a lectin which shows affinity for cf-D-mannose and ce-o-glucose 
residues. When a sample was applied to a column of Concanavalin A-
agarose, however, the active component passed through the column 
unbound. 
Chromatofocusing was used in an attempt to separate the compon-
ents of the DEAE-cellulose fraction by their isoelectric points. The 
active material remained bound to the column and was only eluted 
with 1 M NaCl, suggesting that the material has an isoelectric point less 
than 4.0. 
Separation of the DEAE-cellulose fraction on a column of Sepharose 
6B showed the presence of very high molecular weight components 
which eluted at or near the void volume. Excluded material on this 
column would be expected to have a molecular weight near 1 X 10 6. A 
column of Fractogel TSL HW-65F, which fractionates polysaccharides 
in a molecular weight range of 1 X 10 4 to 1 X 106, was prepared in 
0.05 M (NH 4)2CO 3. A sample of the DEAE-cellulose fraction was 
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Fig. 1. Gel filtration of DEAE-cellulose fraction on Fractogel TSK HW-65F. A 
1.5 cm x 45 cm column was equilibrated in 0.05 M (NH4)2CO 3, pH 7.7. Neutral 
sugar was monitored by phenol-sulphuric acid assay and absorbance at 490 nm was 
measured (A). Protein was assayed by the Lowry method, and absorbance at 
660 nm was measured (A). 10P was monitored as explained in the Experimental 
section (o). 
separated on this column as seen in Fig. 1. The column effluent was 
monitored by the phenol—sulphuric acid colorimetric test for carbo-
hydrates, and individual tubes were analyzed for neutral sugar and I0P-
lowering activity. 
Neutral sugar composition of the individual fractions of the Fractogel 
TSK HW-65F chromatography was determined by g.c. analysis of the 
alditol acetates. The results are plotted in Fig. 2. The most active frac-
tion correlates with the neutral sugar composition which is highest in 
rhamnose and galactose as shown in Table 3 and indicated on Fig. 2. 
The IOP-lowering activity for the individual fractions obtained after 
gel filtration chromatography as shown in Fig. 1 indicates that only 
those fractions in the intermediate area of the fractionation range 
exhibit activity. These tubes were pooled and designated fraction 2. 
Fractions 1 and 3 were also pooled as indicated in Fig. 1. The molecular 
weight range of the active fraction was estimated between 5 X 10 5 and 
1 X 106 by calibrating the Fractogel column with a dextran sample of 
5 X 10 5 average molecular weight. Attempts to assess the homogeneity 
and molecular weight of each fraction by conventional polyacrylamide 
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Fig. 2. Neutral sugar composition (mol% of total sugar) of individual fractions 
obtained from Fractogel TSK HW-65F chromatography of the DEAE-cellulose 
fraction. The sugars indicated are as follows: rhamnose (e); galactose (A); glucose 
(■); arabinose (o); xylose (A). 
TABLE 3 
Neutral Sugar Composition' of Fractogel 
TSK HW-65F Most Active Fraction 








a Determined by g.c. analysis of alditol 
acetates. 
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TABLE 4 
Neutral Sugar Composition' (Mol Per Cent of Total Neutral Sugar) 
of Fractogel TSK HW-65F Pooled Fractions 
Sugar Fraction 1 Fraction 2 Fraction 3 
Rhamnose 19.8 27.9 12.7 
Arabinose 9.8 9.9 38.1 
Xylose 7.6 11.5 4.0 
Mannose 10.6 6.1 4.5 
Galactose 12.2 25.0 29.8 
Glucose 27.2 14.1 9.5 
Glucosamine 12.8 5.6 1.4 
a Determined by g.c. analysis of alditol acetates. 
TABLE 5 
Partial Amino Acid Composition (Mol Per Cent) of Fractogel 
TSK HW-65F Pooled Fractions' 
Amino acid Fraction 1 Fraction 2 Fraction 3 
Aspartic acid 12.0 11.6 13.7 
Threonine 7.3 7.2 7.0 
Serine 6.6 6.6 7.0 
Glutamic acid 11.6 10.5 12.3 
Glycine 10.6 9.4 9.9 
Alanine 10.6 10.1 10.7 
Valine 6.6 4.7 5.9 
Methionine 1.2 1.1 1.2 
Isoleucine 5.3 4.7 4.7 
Leucine 12.7 17.9 8.4 
Tyrosine 3.7 7.6 5.0 
Phenylalanine 4.3 3.9 3.1 
Histidine 1.7 0.3 7.9 
Arginine 5.8 4.5 3.1 
a Lysine was not resolved from ammonia. The amino acid analyzer 
was not equipped with a 440 nm channel for detecting proline 
and hydroxyproline. 
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gel electrophoresis (using 3.75% gel) were unsuccessful since the high 
molecular weight material would not enter the gel matrix. Summaries 
of the carbohydrate and partial amino acid analyses data for these 
fractions are given in Tables 4 and 5, respectively. A summary of the 
purification scheme routinely used and typical yields obtained for the 
isolation of active material is shown in Fig. 3. 
The high content cif galactose in the active fraction 2 suggested that 
further purification might be possible using the Ricinus communis 
lectin which specifically binds 0-'3-galactose. A sample of fraction 2 
was applied to a Ricin—agarose affinity column which was successively 
eluted with the starting buffer, buffer containing 10 mm 0 -methyl -n-
galactopyranoside and buffer containing 200 mm 0-methyl-D-galacto-
pyranoside. The sugar composition and IOP-lowering activity of the 
resulting three fractions are shown in Table 6. The bulk of the material 
and most of the activity eluted with the starting buffer. Again, the 
sugar composition of this active fraction shows a high percentage of 
rhamnose and galactose. 
Since the high molecular weight of the active fraction poses prob-
lems in purification and characterization, several methods were 
DRIED PLANT MATERIAL (1.00 kg) 
Hot H 2 O Extraction 




FRACTION 	(5.08 g) 
Gel Filtration 
FRACTION 1 FRACTION 2 FRACTION 3 
(0.162 g) 	(0.275 9) 	 (4.36 g) 
Fig. 3. Purification scheme for isolation of 10P-lowering active material from 
Cannabis sativa. 
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TABLE 6 
Neutral Sugar Composition (Mol Per Cent of Total Neutral Sugar) Obtained from 





Unbound 	20 mm 
fraction Methyl Gal 
200 mm 
Methyl Gal 
Rhamnose 27.9 29.5 20.7 10.2 
Arabinose 9.9 12.4 21.6 12.6 
Xylose 11.5 7.8 3.5 9.4 
Mannose 6.1 5-0 1.9 8.7 
Galactose 25.0 24.0 43.8 31.5 
Glucose 14.1 14.7 6.1 26.0 
Glucosamine 5.6 6.7 2.3 1.6 
I0P-lowering activity' -47.6 -50.4 -12.8 -9.9 
a 21.tg dose, 4-7 h average fall. 
attempted to reduce the size of the material and yet retain activity. 
Two methods were tried, one which specifically cleaves amino acid 
linkages and one which cleaves 0-glycosidic bonds. 
A sample of the DEAE-cellulose fraction was digested extensively 
with pronase, a mixture of nonspecific proteases which digests peptides 
to free amino acids. The digested sample was applied to a gel filtration 
column. Compared with the original elution profile of the DEAE-
cellulose fraction, the high molecular weight peaks shifted slightly to 
lower molecular weight. Also, the low molecular weight peak broadened. 
The activity profile, however, remained the same. 
An active fraction obtained from gel filtration was treated with 
alkaline borohydride which hydrolyzes O-glycosidic bonds. This sample 
was polydisperse in molecular weight when reapplied to the Fractogel 
column and was not active. 
Our work indicates that the water-soluble component from Cannabis 
sativa that is active in lowering IOP is of high molecular weight (between 
5 X 105 and 1 X 106 daltons) and primarily a carbohydrate-containing 
material. From chromatofocusing studies, the isoelectric point of the 
active material appears to be less than 4.0. Rhamnose, galactose and 
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uronic acids are the major sugar constituents. The active material does 
not bind on columns of Concanavalin A or Ricinus communis lectin 
suggesting that oe-D-glucose, u-D-mannose, or 0-D-galactose are not 
present in bindable locations on the material. The composition of the 
components and its extraction from plant tissue by hot water suggest 
that the active (IOP-lowering) material is a pectic polysaccharide. 
The high molecular weight of this material has posed problems both 
in separation procedures and in formulating a mode of action for the 
component. Chaotropic (0.2 M LiBr) and denaturing solvents (4 m 
guanidine-HC1; 0.5 m NaC1-0.005 m EDTA) have not affected the 
apparent molecular weight of the material as determined by gel filtra-
tion; the amino acid composition also does not show the presence of a 
large number of nonpolar residues that might enhance aggregation of 
several discrete components. Digestion with a nonspecific protease 
does not affect IOP-lowering activity, whereas extensive degradation of 
carbohydrate with alkaline borohydride destroys activity. These results 
in conjunction with the sugar composition data suggest that we might 
be dealing with a cell wall component (Aspinall, 1980; McNeil et al., 
1984). 
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ABSTRACT 
Some biochemical factors of the iris-ciliary 
body of the rabbit have been examined for effects 
induced by water-soluble marihuana-derived materi-
al (MDM). Adenylate cyclase activity and sensi-
tivity to 8-adrenergic agonists were unchanged, as 
measured 4 hours after MDM administration in vivo. 
Magnesium-dependent and anion-sensitive, but not 
sodium-potassium, ATPase activities were inhibited 
6 hours after MDM administration in vivo, although 
they were unaffected by in vitro incubation. 
Topical administration of a potent substance P 
antagonist had no effect on the time course or 
magnitude of intravenous MDM-induced ocular ef-
fects in rabbit. Intravenously administered sug-
ars antagonized the effects of MDM on intraocular 
pressure. A variety of drugs which display a 
range of biochemical effects varying from 
beta-adrenergic receptor agonism, to alteration of 
glycoprotein residues were employed. None of the 
agents employed, ranging from cAMP modifiers to 
protein synthesis blockers, had any effect on the 
MDM-induced response. It is apparent that the 
mechanism underlying the ocular hypotensive effect 
of MDM does not reside in mediation through adeny-
late cyclase, ATPase or substance P, but rather 
through a mechanism mediated by terminal sugar 
moieties on the molecule. The data suggest that 
modification of the surface membrane glycoprotein 
residues on the ciliary epithelium can induce 
marked alterations in aqueous humor flow rate. 
INTRODUCTION 
Water-soluble materials derived from marihuana 
(MDM) have been shown to be highly effective in 
reducing intraocular pressure (TOP) in rabbits 
following intravenous injection (1,2). These 
materials have been chemically identified as a 
rhamnogalacturanon containing some protein (3,4), 
and detailed analyses of purified extracts have 
been made (4). Prior studies have indicated that 
many antagonists, including adrenergic agents, 
prostaglandin inhibitors, parasympathetic agents, 
and steroids (1,2), have failed to block the TOP-
reducing effects of this material, and its mecha-
nism of action has been elusive. 
Biochemical studies of the iris/ciliary pro- 
cesses might provide information relevant to un-
derstanding of how MDM could exert such a profound 
effect on IOP. Studies were made, therefore, of 
the effects of MDM on the activities of adenylate 
cyclase and ATPases in the iris/ciliary body, and 
of the action of MDM in the presence of a sub-
stance P antagonist. Some of the biochemical 
techniques employed, although in vitro in nature, 
have been previously shown to reflect the effects 
of prior in vivo treatment regimens to various 
drugs (5-7). Further studies have also been made 
on the effect of amino sugars on the MDM-induced 
response, following the initial observation that 
sugars reduce the MDM effect in rabbits. A vari-
ety of other antagonists or modulators of protein 
and glycoprotein synthesis have been used in at-
tempts to modify the response to MDM as it has 
become apparent that MDM appears to induce a fall 
in IOP by methods which have not previously been 
demonstrated in the eye (8). These modulators of 
biochemical events were chosen to alter the ocular 
status with regard to specific or generalized 
responses which could interact with MDM. Evidence 
is accumulating that MDM appears to act through 
effects on membranes within the eye, particularly 
those related to aqueous humor production (2,8). 
MATERIALS AND METHODS 
Adult albino rabbits, 2-3 kg, were used. MDM 
was used in either solid or liquid form (4). The 
solid form (MDM #1), although powerful in terms of 
induction of a fall in TOP was less potent than 
the more purified liquid form (MDM #2). The rea-
son for the material being in liquid form was 
merely to enable very small pg quantities to be 
made accurately in small volumes (385 vg/1000 pl 
or 1.93 pg/5 pl), as volumetric measurements of 




this size are more readily made than gravimetric 
measurements. MDM was always given intravenously. 
The experiments can be divided into five groups: 
Group I - Adenylate Cyclase Activity  
Experimental rabbits received 200 pg MDM #1 (in 
normal saline)/animal via an ear vein, and were 
killed 4 hours afterwards, when the 10P is minimal 
(1,2) (minimum IOP is reached at 4 hours but sus-
tained for several more hours), while control 
rabbits received the saline vehicle and served as 
paired controls. Adenylate cyclase activities 
were determined on membrane fragments, using di- 
32 
rect assay with 32P-ATP, prepared from a treated 
and untreated pair. The methodology followed that 
of Mittag and Tormay (5) to determine the 
stimulation index, with control enzyme activities 
under each assay condition expressed as 100%. 
Tissues were collected from enucleated eyes and 
homogenized in Tris-buffer (5). Homogenates were 
centrifuged, the supernatant decanted, and the 
membranes resuspended in Tris-buffer. Drugs were 
added, as needed, after a 2 min incubation at 
30 ° C, and preincubated for an additional 2 min 
before addition of substrate prior to a final 10 
min incubation. 
Group II - ATPase Activity  
Treatment was made with MDM #1 either in vivo 
(200 to 400 pg/rabbit), or in vitro (5 to 12 pg 
per 20 mg protein). A parallel in vivo control 
series with saline injection was also employed. 
In all experiments, the iris-ciliary body was 
removed and shaken with 2 ml of Tris-buffer in a 5 
ml glass bottle containing small glass beads (6). 
This suspension of epithelial cells was diluted to 
10 ml, which gave approximately 200 pg protein/ml. 
With in vivo treatment, tissues were removed at 6 
hours after injection; whereas, for in vitro 
studies, MDM was either added directly to the 
assay tubes or allowed to interact with the 
homogenate for 4 hours. The assay procedures for 
ATPase activity were those described previously 
(7) for the determination of Mg
2+
, 
Na,K-stimulated, and anion-sensitive fractions, 
with incubation in a Tris-buffered solution at pH 
7.95. 
Group III - Substance P Antagonist  
One of the responses to systemic MDM in rabbits 
is a slight rise in aqueous humor protein (1), and 
substance P may be a candidate for the mediator of 
some of the ocular responses to MDM. Substance P 




-SP) (9) was 
added topically to the right eye of conscious 
rabbits at either 0.1 or 10 4M in a 50 pl drop. 
MDM #1 was injected intravenously at 100 pg/animal 
1 hour afterwards. IOP was measured hourly using 
an Alcon pneumatonograph, and the percentage 
change in TOP was calculated with reference to the 
mean of a 30 min and 0 min reading, prior to drug 
addition. 
Group IV - Sugar Antagonism  
Sugars were given intravenously in a volume of 2 
or 3 ml at a dose of 1 gram/animal 1 hour prior to 
systemic injection of various doses of MDM #1 (5, 
10, 25, or 50 pg/animal). A time zero IOP value 
was obtained and the IOP determined hourly for up 
to 8 hours. Frequently a parallel series of ex-
periments was run with MDM alone for direct com-
parison with the sugar/MDM animals as the cost of 
the amino sugars was high, thereby precluding an 
independent series of amino sugar controls. Pre-
vious studies (2) have indicated that the intrave-
nous injection of several sugars did not induce a 
fall in IOP. 
Group V - Antagonists and Agonists  
Several antagonists or agonists were used; their 
properties and doses are listed in Table 1. Theo-
phylline was used both topically and intravitreal-
ly; isoproterenol was used in a 4% topical drop 
form (50 p1); guanosine 5'(-1,=-imido)triphos-
phate, sialic acid (N-acetylneuraminic acid), 
tunicamycin, and actinomycin D were all used in-
travitreally. All the preceding drugs were ob-
tained from Sigma Chemical Company. SITS 
(4-acetamido-4'-isothiocyanato-stilbene-2-2'-disu-
lfonic acid) (Gallard-Schlesinger Chemical Manu-
facturing Co.) and mannose-6-phosphate and yeast 
mannan (Sigma) were used both intravitreally and 
intravenously. Each drug was chosen for its abil-
ity to alter a specific primary biochemical event, 






Agonists and antagonists used against MDM #2 (5 pl 	[1.93 pg]/rabbit), 
their mode of action, dose level, and route of administration 








































































Numbers in parentheses are reference numbers to the effects of each compound. 
The drug concentration chosen was based upon lit-
erature values in the cell systems where the drug 
had exerted an influence on a biochemical process 
at at least one half the concentration used here. 
While only one concentration of each potential 
antagonist was employed per route of adminis-
tration, the dose levels were higher than those 
known to induce effects in other systems (10-23) 
and there is no reason to suspect that the eye is 
any less sensitive than other organs. In addi-
tion, at least 4 of the compounds were used via 
two routes of administration, either intravitreal 
and/or topical or systemic. 
For all drugs, MDM #2 was given intravenously in 
liquid form at a dose of 5 pl/rabbit (1.93 pg 
total dose) which normally induces a fall in IOP 
of about 40% (1,2,4). Following intravitreal 
injections of an antagonist, MDM was administered 
24 hours later; following topical application or 
intravenous injection of agonist or antagonist, 
MDM was given 30 minutes later. Twenty-four hours 
was deemed sufficient time for any antagonist not 
only to reach the target tissue (in this case, the 
ciliary body) but to induce and sustain a pharma-
cological response. Since the loss of sucrose 
(342 daltons) from the vitreous has a half-life of 
15 hours (24), the choice of 24 hours appears 





molecular weight, given the induction of a re-
sponse in addition to the the diffusion time. 
RESULTS 
Group I - Adenylate Cyclase Activity  
The intravenous injection of 200 to 400 pg MDM 
#1/rabbit in Groups I and II results in a fall in 
IOP of about 60% (1,2) beginning at about 4 hours 
and lasting for several hours. Under the assay 
conditions for adenylate cyclase, minimal changes 
Table 2 
Adenylate cyclase activities of iris-ciliary 
body from MDM-treated rabbits 
Assay Condition 
% of Control 
Activity 
Base activity 119 ± 	9.9 
+ 2 x 10
-2
M NaF 97 ± 	21.4 
+10
-5
M isoproterenol 114 ± 	11.6 
+10
-4
M GTP 113 ± 	9.2 
+ 2 x 10
-7 
GppNHp 99 t 	9.6 
+isoproterenol + GppNHp 104 ± 	5.5 
+isoproterenol + GTP 123 t 	17.4 
Values are the mean ± SEM for 4 experiments under each 
condition, and are given relative to parallel control, 
paired tissue activities. Rabbits received 200 to 400 
og MDM #1 and were assayed at 4 hours after injection. 
were found, although variable results were ob-
tained with NaF, and isoproterenol plus GTP, as 
indicated by the large standard errors (Table 2). 
It appears that MDM has no significant effect on 
ciliary epithelial adenylate cyclase nor on the 
responsiveness to 9-adrenergic agonists and guanyl 
nucleotides. 
Group II - ATPase Activity 
The ATPase assays (Table 3) show that, although 
the Na,K-sensitive fraction is unchanged by prior 
in vivo treatment with 200 to 400 pg MDM #1 per 





creased. In vitro treatment (5 to 12 pg per 20 mg 
protein) does not cause a change in any ATPase 
activity (except for the expected aging of the 
Na,K fraction; data not shown). It is apparent, 
therefore, that in vivo MDM reduces the activity 
of Mg
2+ 
(28%) and anion-sensitive ATPase (29%) in 
the ciliary epithelium. 
Group III - Substance P Antagonist  
Substance P antagonist, although inhibiting both 
the irritant effects of exogenous substance P and 
the inflammatory response to infrared irradiation 
of the iris (9), had no effect on the ocular re-
sponse to 100 pg MDM #1 per rabbit at concen-
trations far greater than those which prevent 
aqueous flare and miosis after exogenous substance 
P (9). The maximal percentage falls in IOP caused 
by MDM (at 360 minutes after administration) were 
Table 3 
Effect of MDM on ATPase of the rabbit ciliary body 
Mg





Control 13.0 ± 	0.7 3.3 ± 0.2 8.4 t 0.4 9 
In Vivo Treated 9.3 ± 0.4
+ 
3.1 ± 0.4 6.0 t 0.4 6 
(6 hours after 
injection) 
In Vitro Treated 13.6 ± 	0.7 3.2 ± 0.2 7.9 ± 0.4 8 
(4 hours incubation) 
Values are the mean ± SEM of n tissues, and are in p moles P i liberated from ATP 
per hour per mg protein. +, P < 0.001 compared to control values. Rabbits 
received 200 to 400 pg MDM #1 per animal for in vivo determinations, and were 




as follows: 	control eye, 35.2 ± 3.9%, paired 
substance P antagonist-treated eye, 0.1 pM, 37.9 ± 
4.4%; control eye, 45.2 ± 4.8%, paired 10 pM 
substance P antagonist-treated eye, 42.4 ± 5.0%. 
Antagonism of possible substance P activity in the 
eye evidently is without effect on the ocular 
response to MDM, despite known ocular effective-
ness for 7 hours (9). 
Group IV - Sugar Antagonism 
Intravenous galactosam:ine caused a significant 
inhibition of the MDM-induced fall in TOP at 5, 
25, and 50 pg of MDM #1, whereas glucosamine 
caused an inhibition at /1DM doses of 5 and 50 pg. 
Xylose did not modify the MDM-induced response, 
and rhamnose inhibited the response only at 5 pg 
MDM (Table 4). These responses do not follow a 
true dose-response relationship, however, and may 
reflect individual rabbit differences in response  
to MDM, with some responding more than others. 
Group V - Antagonists and Agonists  
MDM (1.93 pg) was always given intravenously 
against various antagonists given either topi-
cally, intravitreally, or intravenously (Table 5). 
In no case was a statistically significant differ-
ence found between drug + MDM and MDM alone which 
would suggest an effect of any antagonist on the 
normal progression of the ocular response to MDM. 
DISCUSSION 
Supramaximal doses of MDM were used in several 
experiments in order to accentuate any possible 
changes which might have occurred and to ensure 
that a maximal response would be obtained with 
regard to the fall in TOP (1,2). The times chosen 
for the biochemical analyses were selected to 
coincide with the maximal fall in TOP, relying 
Table 4 





















5 28.1 27.3 24.3 14.9* 25.4 17.3* 
± 	1.2 (8) ± 0.8 ± 0.8 (8) ± 	4.1 ± 0.8 (8) ± 	3.7 
10 25.4 24.5 25.6 24.2 22.4 24.4 
± 	1.1 (4) ± 	3.6 ± 	1.8 (4) ± 6.6 ± 0.4 (8) ± 	3.7 
25 26.2 49.9 26.0 21.7* 24.3 41.2 
± 	1.2 (8) ± 	2.9 ± 0.8 (8) ± 	5.4 ± 0.8 (8) ± 2.1 
50 27.8 60.1 23.2 48.9* 23.0 44.3* 











5 22.8 20.8 24.9 16.4* 
± 	0.7 (8) ± 	3.8 ± 0.6 (8) ± 4.3 
10 25.5 34.8 25.1 37.8 
± 0.8 (8) ± 	5.6 ± 0.7 (8) ± 	3.6 
25 25.0 49.7 24.6 42.0 
± 	0.7 (8) ± 	4.2 ± 0.7 (8) ± 3.2 
50 
The values represent the mean ± SEM of the percentage fall in TOP 6 hours after the 
time-zero value (given in mm Hg). *, P < 0.05 compared to "no sugar" values. 






Effects of agonists and antagonists 




Maximal Fall in TOP 
n 
MDM Alone 
(5 ul) n 




M Topical 40.8 I- 	3.7 24 47.7 	± 8.5 8 
10
-2  
M Intravitreal 46.7 ± 	7.2 8 38.7 ± 5.1 8 





M Intravitreal 43.9 ± 6.2 8 50.1 ± 	7.2 8 
Mannose-6-phosphate 10
-3 
M Intravitreal 41.5 	± 5.2 8 40.5 ± 8.0 8 
10 mg Intravenous - 37.1 ± 3.7 8 
Sialic acid 10
-4 
M Intravitreal 39.8 	± 	4.5 7 49.9 	± 	3.9 7 
Tunicamycin 2 ug/ml Intravitreal 49.2 t 	1.5 4 57.4 	± 2.4 4 
Actinomycin D 10
-5 
M Intravitreal 35.5 	± 	5.2 8 50.2 	± 	2.9 7 
SITS 1.1 mg Intravitreal 45.3 	± 8.5 4 32.8 ± 8.5 4 
29.9 ± 4.0 4 41.4 ± 3.5 4 
83 mg Intravenous 38.2 ± 4.7 4 34.6 	t 	4.9 4 
Yeast mannan 10 mg Intravenous 50.9 ± 3.1 8 
10 pg Intravitreal 43.9 	± 	1.7 8 55.1 	± 	3.2 4 
The maximal fall in TOP is given as the % change from an initial base-line IOP which 
is an average of a -30 and 0 time IOP, and is given as the mean ± SEM of n eyes. The 
time of the maximal fall was 5 hours after 5 ul (1.93 pg) of MDM #2 injection unless 
otherwise indicated. 
upon the relationship between this event and any 
biochemical changes to be temporally related. The 
absence of any effects could possibly be the re-
sult of biochemical events being concluded and 
returned to normal levels following the initiation 
of the IOP changes, but this is considered un-
likely in view of the slow induction of the fall 
in IOP and its longevity. 
These studies indicate the absence of effects of 
MDM on adenylate cyclase of the iris-ciliary body, 
or on possible substance P activity in the eye. 
MDM significantly reduced the Mg
2+ 
ATPase, and 
anion-sensitive ATPase, of the iris-ciliary body, 
but had no effect on the Na,K-stimulated ATPase. 
While the bicarbonate-sensitive ATPase could pos-
sibly play a role in the secretion of bicarbonate  
ions, a role of the Mg 2+ ATPase in aqueous humor 
formation is at present unknown. 
Previous studies (25) with intravitreal ouabain 
(0.5 lig) have indicated that a fall of 78% in 
aqueous humor inflow was associated with a 70% de-
crease in Na,K-ATPase activity (almost a 1:1 rela-
tionship) and no change in Mg
2+ 
ATPase activity. 
It is possible that inhibition of certain ATPases 
can interfere with aqueous inflow, but two factors 
must be considered. First, the role of the Mg
2+ 
and anion-sensitive ATPases are not known at pre-
sent; this does not preclude their involvement in 
aqueous humor inflow, but the demonstrated link 
between Na,K-ATPase and aqueous inflow (25) argues 
against a direct involvement for the other 





corresponds directly to a fall in aqueous inflow, 
as shown previously (25), then only a 30% fall in 
aqueous inflow would be predicted based upon the 
level of enzyme inhibition. Thus, unless there is 
considerable biochemical amplification associated 
with the inhibition of the Mg
2+ 
ATPase or the 
anion-sensitive ATPase, it is difficult to recon-
cile the measured changes with the large (> 70%) 
inhibition of aqueous Flow (1,2). It appears 
unlikely, therefore, that the inhibition of Mg
2+ 
and anion-sensitive ATPases found here is related 
to the fall in aqueous humor inflow (1,2). 
The absence of a respcnse of adenyl cyclase to 
MDM differs from the response induced by cholera 
toxin (26); intravitreal and intraarterial in-
jections of microgram quantities of the latter 
compound induced both a 50% fall in aqueous humor 
inflow and a stimulation of adenylate cyclase by 
at least two-fold. With cholera toxin, the two 
events occurred simultaneously over many hours. 
The effects of MDM and cholera toxin, both of 
which cause large reductions in IOP, appear to 
have a different biochemical basis. 
Previous studies (1) have shown that prosta-
glandins are not involved in mediation of the 
response to MDM, and it appears that substance P 
is similarly excluded from participation in the 
MDM response as judged by the magnitude of the MDM 
response under the influence of the substance P 
antagonist. If MDM caused the release of sub-
stance P, it could further induce an increase in 
aqueous protein and a related inflammatory situa-
tion; the present data indicate that this is un-
likely. 
None of any of the other drugs tested, at least 
at the doses employed herein, caused any change in 
the MDM-induced response (Table 5). The concen-
tration of all potential agonists or antagonists 
was higher than that needed in other systems to 
induce substantial effects (10-23) and the eye 
should, a priori, act in a similar manner to other 
organs towards the compound if any response were 
to be initiated. Several compounds were given at 
different doses via different routes, and these 
results substantiate the absence of any effect on  
the ocular exposure to MDM. That none of the pro-
tein or glycoprotein synthesis inhibitor compounds 
had any effect may reflect a potentially very slow 
turnover of epithelial cells in the ciliary epi-
thelium. Preliminary studies using 
3
H-thymidine 
indicate no (or at best very few) mitotic figures 
in either layer of the ciliary epithelium when 
tissues are examined after 1, 3, or 5 days after 
thymidine injection or between 7 days and 74 days 
of thymidine in the drinking water (McDonald, 
Elijah, and Green, unpublished data). 
The partial inhibition of the MDM effect caused 
by intravenous galactosamine and glucosamine ex-
tend previous observations (2) where galactose, 
glucose, and mannose also caused some reduction of 
the MDM-response at 25 pg MDM. MDM has been found 
to contain 32 mole percent rhamnose of total sug-
ar, 11 mole percent of xylose, 5 mole percent 
glucosamine, 16 mole percent glucose and 24 mole 
percent galactose (4). Thus, it may be that 
galactose and glucose, although not being the 
major sugars by analysis, may be important sugar 
residues in eliciting the ocular response to MDM. 
The present data suggest that MDM might be act-
ing to reduce IOP and aqueous humor inflow by a 
mechanism related to interaction with the terminal 
sugar moieties of the glycoproteins in the ciliary 
epithelium or by some modification of intracellu-
lar component by a cell-membrane permeable metabo-
lite. Structural or chemical modification of 
surface proteins or intracellular events could 
induce profound effects on aqueous humor inflow. 
This perhaps suggests that other mechanisms exist 
for potential manipulation of intraocular pres-
sure. Based upon the result that MDM acts only 
when given intravitreally in the monkey (2), we 
suggest that MDM acts at the basal surface of the 
non-pigmented epithelium. The identification of 
MDM may have revealed a unique means of affecting 
aqueous humor inflow. 
ACKNOWLEDGEMENT 
Supported in part by PHS Research Grants EY04572 
(KG), EY02619 (TM), EY00541 (MVR), and EY03352 





by National Glaucoma Research, a program of the 
American Health Assistance Foundation (KG), and in 
part by a departmental award to the Department of 
Ophthalmology, Medical College of Georgia from 
Research to Prevent Blindness, Inc. We thank Mrs. 
Sylvia Catravas for excellent secretarial assis-
tance and Professor K. Folkers, Institute for 
Biomedical Research, University of Texas, Austin, 
Texas, for generously supplying the substance P 
antagonist. 
4lnstitute of Biological Sciences, Oakland University, 
Rochester, MI 48063, 5 School of Chemistry, Georgia 
Institute of Technology, Atlanta, GA 30332 and 
6Department of Chemistry, Kennesaw College, Marietta, 
GA 30061, USA 
CORRESPONDING AUTHOR 
Keith 	Green, 	Ph.D., 	D.Sc., 	Department 	of 
Ophthalmology, Medical College of Georgia, MCG Box 
3059, Augusta, GA 30912, USA. 
REFERENCES 
1. Green, K., Zalkow, L.H., Deutsch, H.M., 
Yablonski, M.E., Oliver, N., Symonds, C.M. 
and Elijah, R.D. (1981) Ocular and systemic 
responses to water soluble material derived 
from Cannabis sativa (Marihuana). Curr. Eye 
Res., 1, 65-76. 
2. Green, K., Symonds, C.M., Elijah, R.D., 
Zalkow, L.H., Deutsch, H.M., Bowman, K. and 
Morgan, T.R. (1982) Water soluble marihuana-
derived material: pharmacological actions in 
rabbit and primate. 	Curr. Eye Res., 2, 
599-608. 
3. Deutsch, H.M., Green, K. and Zalkow, L.H. 
(1981) 	Isolation of ocular hypotensive 
agents from Cannabis sativa. 	J. Clin. 
Pharmacol., 21, 479S-485S. 
4. Hodges, L.H., Deutsch, H.M., Green, K. and 
Zalkow, L.H. (1984) Polysaccharides from 
Cannabis sativa active in lowering intra-
ocular pressure. Carbohydrate Polymers (in 
press). 
5. Mittag, T. and Tormay, A. (1981) Desensi- 
tization of the I3-adrenergic receptor-
adenylate 	cyclase 	complex 	in 	rabbit 
iris-ciliary body induced by topical epi-
nephrine. Exp. Eye Res., 33, 497-503. 
6. Riley, M.V. (1964) 	The sodium-potassium- 
stimulated adenosine triphosphatase of rabbit 
ciliary epithelium. 	Exp. Eye Res., 3, 
76-84. 
7. Riley, M.V. (1977) Anion-sensitive ATPase in 
rabbit corneal endothelium and its relation 
to corneal hydration. 	Exp. Eye Res., 25, 
483-494. 
8. Green, K. (1982) Marihuana and the eye: A 
review. J. Toxicol.-Cut. & Ocular Toxicol., 
1, 3-32. 
9. Tfolmdahl, G., Hakanson, R., Leander, S., 
Rosell, S., Folkers, K. and Sundler, 5. 
(1984  A substance P antagonist, [D-Pro , 
D-Trp ' 7 ] SP, inhibits inflammatory responses 
in the rabbit eye. Science, 214, 1029-1030. 
10. Orloff, J. and Handler, J.S. (1962) 	The 
similarity of effects of vasopressin, 
adenosine-3',5'-monophosphate (cyclic AMP) 
and theophylline on toad bladder. J. Clin. 
Invest., 41, 702-709. 
11. Eakins, K.E. (1963) 	The effect of intra- 
vitreous injections of norepinephrine, epine-
phrine and isoproterenol on the intraocular 
pressure and aqueous humor dynamics of rabbit 
eyes. J. Pharm. Exp. Therap., 140, 79-84. 
12. Cooke, B.A. (1983) The regulation of adeny-
late cyclase by glycoprotein hormones. In 
"Current Topics in Membranes and Transport", 
(eds. Kleinzeller, A. and Martin, B.). Vol. 
18. 	Academic Press, New York. pp. 143-177. 
13. Pfeuffer, T. 	(1977) 	GTP-binding proteins 
in membranes and the control of adenylate 
cyclase activity. 	J. 	Biol. 	Chem., 	252, 
7224-7234. 
14. Shepherd, V., Schlesinger, P. and Stahl, P. 
(1983) Receptors for lysosomal enzymes and 
glycoproteins. In "Current Topics in Mem-
branes and Transport", (eds. Kleinzeller, A. 
and Martin, B.). Vol. 18. Academic Press, 
New York. pp. 317-338. 
15. Kaplan, A., Achord, D.T. and Sly, W.S. 
(1977) Phosphohexosyl components of a lyso-
somal enzyme are recognized by pinocytosis 
receptors on human fibroblasts. Proc. Natl. 
Acad. Sci. USA, 74, 2026-2030. 
16. Stahl, P.D., Rodman, J.S., Miller, M.J. and 
Schlesinger, P.D. 	(1978) Evidence for re- 
ceptor-mediated binding of glycoproteins, 
glycoconjugates, and lysosomal glycosidases 
by alveolar macrophages. Proc. Natl. Acad. 
Sci. USA, 75, 1398-1403. 
17 	Duksin, D. and Bornstein, P. (1977) 	Changes 
in surface properties of normal and trans-
formed cells caused by tunicamycin, an inhib-
itor of protein glycosylation. Proc. Natl. 
Acad. Sci. USA, 74, 3433-3437. 
18. Keefer, L.M. and De Meyts, P. (1981) Glyco-
sylation of cell surface receptors: tunica-
mycin treatment decreases insulin and growth 
hormone binding to different levels in 
cultured lymphocytes. Biochem. Biophys. Res. 
Comm., 101, 22-29. 
19. Surani, M.A.H. (1979) Glycoprotein synthe-
sis and inhibition of glycosylation by tuni-
camycin in preimplantation mouse embryos: 
compaction and trophoblast adhesion. 	Cell, 
18, 217-227. 
20. Crabbe, J. and De Weer, P. (1964) Action of 
aldosterone on the bladder and skin of toad. 
Nature, 202, 298-299. 
21. Knauf, P.A. and Rothstein, A. (1971) Chemi-
cal modification of membranes. 1. Effects 
of sulfhydryl and amino reactive reagents on 





red blood cell. 	J. Gen. Physiol., 58, 
190-210. 
22. Rothstein, A., Cabantchik, Z.I. and Knauf, P. 
(1976) Mechanisms of anion transport in red 
blood cells: 	role of membrane proteins. 
Fed. Proc., 35, 3-10. 
23. Saito, Y. and Wright, E.M. 	(1983) Bicar- 
bonate transport across the frog choroid 
plexus and its control by cyclic nucleotides. 
J. Physiol., 336, 635 -648. 
24. Bito, 	L.Z. 	and 	Salvador, 	E.V. 	(1972) 
Intraocular fluid dynamics. III. The site 
and mechanism of prostaglandin transfer 
across the blood intraocular fluid barriers. 
Exp. Eye Res., 14, 233-241. 
25. Bonting, S.L. and Becker, B. (1964) Studies 
on 	sodium-potassium 	activated 	aden- 
osinetriphosphatase. XIV. Inhibition of 
enzyme activity and aqueous humor flow in the 
rabbit eye after intravitreal injection of 
ouabain. Invest. Ophthalmol., 3, 523-533. 
26. Gregory, D., Sears, M., Bausher, L., Mishima, 
H. and Mead, A. (1981) 	Intraocular pres- 
sure and aqueous flow are decreased by 
cholera toxin. 	Invest. Ophthalmol. Vis. 





FINAL PROGRESS REPORT 
EY03342 
04/01/80-08/31/85 
‘/ _3 - 0S- 
 
DR. L. H. ZALKOW, P.I. 
SCHOOL OF CHEMISTRY 
GEORGIA INSTITUTE OF TECHNOLOGY 
ATLANTA, GEORGIA 30332 
ANTIGLAUCOMA COMPOUNDS FROM CANNABIS SATIVA 
The objective for this research as outlined in the initial grant proposal 
in 1980 stated that we would (1) isolate and characterize compounds from 
Cannabis that were active in lowering 10P,, (2) synthesize and screen new 
compounds of similar structural type, (3) synthesize and screen water-soluble 
cannabinoids, and (4) select and screen other plants as possible sources of 
active compounds. As we succeeded in partially purifying and characterizing 
the active compounds isolated from Cannabis, the discovery of the high 
molecular weight of these compounds precluded our initial plan to synthesize 
analogues. Because these compounds contained no similarity to cannabinoids 
and since no water-soluble cannabinoid has been found effective in treating 
glaucoma, we refocussed our efforts on characterizing the very potent high 
molecular weight material and recently on fragmenting it in such a way that 
active smaller molecules could be obtained. We have continued to select and 
screen other plants as well. A summary of the progress made toward these 
objectives is given below. 
A water-soluble material has been isoTated from Cannabis sativa wnicn Is highly active 
in lowering intraocular pressure (IOP) in rabbits. MOM (marijuana-derived-material) 
has been purified —200 times from crude extract to a —500,000 dalton polysaccharide 
material, rich in rhamnose, galactose and galacturonic acid, containing protein rich 
in polar amino acids. Testing of this material for IOP-lowering effects is being 
carried out by Professor Keith Green of the Medical College of Georgia in 
collaboration with us. Professor Green's independently-supported efforts (EY04572) 
are dedicated to the physiological and pharmacological effects of these and other 
materials. MDM lowers IOP in rabbits, after intravenous injection, to 60% of maximum 
fall in IOP at 0.7 pg/animal and to 100% at 3 pg/animal. Injection of 0.01 to 0.001 
pg, intravitreally, results in a similar fall, but the onset is delayed 12-15 hrs and 
the duration of action is even longer. This material is more effective and has a 
considerably longer lasting effect in lowering IOP than cannabinoids. It does not 
have the undesirable side effects of either cannabinoids or other antiglaucoma 
medications. Several lines of evidence suggest the activity is due to a smaller 
portion resulting from  in vivo processing. The active portion of MDM might act as a 
hormone or neurotransmitter. Its mode of action is very different from that of most 
known effector molecules. We propose to cleave MDM either enzymically or chemically 
into fragment(s) without destroying activity. The resulting fragments will be 
characterized as to content of protein, sugar, uronic acids and amino sugars; 
molecular weight; electrophoretic mobility; and IOP-lowering activity expressed as 
ED4n. ED40 
is the estimated dose (in pg) giving a 40% lowering of IOP (60% of 
maximum). This material has potential as a topically active glaucoma medication 
without psychoactive effects. Further study of the physiological effects of the 
active portion of MDM could lead to elucidation of the mode of action of an unknown 
class of receptors. 
We have surveyed a number of other plants. One of them, Burley tobacco, yielded a 
crude extract which is as active as that of Cannabis, but its chemical composition is 
much different. If the differences in compOITITOITTire related to IOP-lowering activ-
ity, isolation of the active portion from Burley might be easier than from Cannabis. 
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